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Aims and outlines  
Measurement of quality of life (QOL) as an indicator of health outcome has become 
increasingly important for cardiac patients, where the goal of treatment is not only 
to improve prognosis, but also to relieve symptoms and improve function. 
Research has demonstrated that variables other than disease symptoms and pain 
are more important to patients for their quality of life. In particular, areas such as 
patients’ physical performance and psychological and social functioning have been 
recognized as important determinants. Also burden of symptoms and perceptions 
of well-being must be considered. In the case of angina pectoris, nitrates can 
effectively control symptoms of angina pectoris and have been demonstrated to 
reduce mortality in patients with acute myocardial infarction. In addition, based on 
the results of the GISSI-3 and the ISIS-4 studies, it is clear that nitrates can be 
safely used for long-term treatment. However, little is known about their net effects 
on current health-related QOL indices. The objective of chapter 2 is to discuss the 
beneficial and harmful effects of nitrates. For that purpose, the results of two 
studies on nitrate therapy in the Netherlands are discussed.  
  
In chapter 2 we conclude that once-daily dosage regimens of isosorbide 
mononitrate (ISMN) are more effective anti anginal treatments than daily 
administration of multiple small doses of the compound. This might be because 
nitrate tolerance is less likely to develop. Nitrates are nitric oxide (NO) donors. 
Patients with coronary artery disease may or may not have endothelial dysfunction 
of coronary arteries and, thus, dysfunctional endogenous NO. Patients with 
dysfunctional endogenous NO production may better benefit from effective nitrate 
treatment than do others. However, this has not been tested. Patients with diabetes 
mellitus, hypertension, smoking, and cholesterolemia, are particularly at risk of 
early endothelial dysfunction. Chapter 3 tries to test the hypothesis that such 
patients might better benefit from effective NO donor therapy than do patients 
without such concomitant conditions. For this purpose we perform a multiple linear 
regression analysis of the comparative study of 1,350 patients with stable angina 
pectoris, treated for 6 months with either 50 mg ISMN administered orally at 8 
 
 
       





hours AM or with standard multiple daily oral doses of the compound. The objective 
of the study is to assess whether the presence of concomitant conditions, 
particularly those associated with early endothelial dysfunction, are independent 
determinants of the better benefit from effective nitrate therapy.   
 
As stated earlier, chronic nitrate therapy administered once-daily may be more 
convenient to patients and may better protect them from nitrate tolerance than 
multiple daily dose nitrate therapy. This was supported by the Dutch study of 
patients with stable angina pectoris as described in chapter 2 and 3: once daily 
therapy improved not only New York Heart Association (NYHA) anginal class and 
patient compliance but also QOL. The primary objective of the study described in 
chapter 4 is to assess whether the above Dutch study was reproducible, and could 
be generalized across nations / populations. The secondary objective is to assess 
the effects of treatment modality on patients' satisfaction with their disease state, 
and on their NYHA heart failure class. In order to reduce between subject variability 
of symptoms, and, thus, enhance the sensitivity of testing, a self-controlled study 
design is chosen with all of the patients starting on multiple dose nitrate therapy, 
and, after 3 months switching to once-daily nitrate therapy for three more months. 
Patients are recruited from hospitals in Germany, Portugal , and the Czech 
Republic.  
 
In the retrospective study described in chapter 3 we found that anginal patients 
with concomitant diabetes or hypercholesterolemia derived more benefit from 
changing over to a once daily regimen than did patients without. In contrast, 
anginal patients with concomitant hypertension or smokers derived less benefit. 
However, retrospective studies are at risk of confounding and recall bias, and have 
to be confirmed by prospective data. The IQOLAN (International Quality Of Life 
ANgina study), an international survey with a focus on QOL in nitrate-treated 
patients with angina pectoris gave us the opportunity to assess this issue 
prospectively in chapter 5. Thus, we assumed that anginal patients with 
comorbidities may better benefit from a once-daily dosage regimen than patients 
 
 
    





without. For that purpose we compare improvements of QOL after 3 month multiple 
dose and after 3 month once daily treatment in patients with and without 
comorbidities.  
 
From the previous chapters we learned that chronic nitrate treatment is safe and 
efficacious for the symptomatic treatment of stable angina pectoris. Once daily 
dosages regimens provided better therapeutic efficacy than did multiple daily 
dosages. Possible explanations included less risk of nitrate tolerance with nitrate 
low periods for several hours per day, better patient compliance with once daily 
dosages, and better protection from the circadian peak frequencies of angina 
pectoris during daytime. Nitrates release NO from the nitrate molecule. NO has a 
vasoprotective potential, because it has vasodilatory, anticoagulant, and 
antioxidative properties, antagonizes leukocyte-adhesion, and smooth-muscle-
proliferation. These effects are assumed to be clinically relevant, substantiated by 
the fact that a variety of cardiovascular conditions such as hypertension, diabetes, 
hypercholesterolemia, and cigarette smoking are associated with an impairment of 
endothelium-dependent NO activity. This could mean, that anginal patients with 
such comorbidities might better benefit from nitrate therapy than their counterparts 
without. The survey in chapter 6 was designed as a multinational study, evaluating 
the effect of a switch from multiple daily to a once-daily nitrate treatment on the 
QOL and anginal symptoms of patients with stable angina pectoris. The first 
objective is to compare predefined quality of life indices and NYHA anginal class 
before versus after replacement of multiple daily with once-daily nitrate therapy, 
and to assess whether the results of the previous chapters are reproducible in a 
larger study and across more countries. The second objective is to investigate the 
influence of cardiovascular risk factors and comorbidities on the observed changes 
in QOL and NYHA anginal class. This is the final chapter concerning nitrate 
therapy. 
 
Chapter 7 focuses on quality of life with heart failure. Patients able to cope with all 
of the unpleasant aspects of their medical condition, generally, have better levels 
 
 
       





of well-being than those unable to cope. What are determinants of “ability to cope”? 
It has been suggested that adequate objective information of patients on their 
physicomedical condition is an important factor. Also, social identification of 
patients with their counterparts has been suggested as a possible contributory 
factor. This may be particularly true for patients from moderate or low social class, 
as not infrequently observed in patients with heart failure. We hypothesized that in 
patients with heart failure “inability to cope” would be associated not only with low 
QOL, but also with lack of adequate medical information and lack of social 
identification with the patients’ counterparts. We also assumed that the latter 
factors may be direct contributors to low QOL. In order to assess these hypotheses 
we study 60 patients with stable chronic heart failure in this chapter. All of the 
patients are assessed by a test battery consisting of validated questionnaires.  
 
Therapeutic interventions have been demonstrated to beneficially influence quality 
of life of patients with cardiovascular conditions. E.g. in the previous chapters we 
showed that once-daily dosage schedules of nitrates significantly improved QOL in 
patients with stable angina pectoris. In the past few years also psychological 
interventions have been successfully employed. Particularly, providing adequate 
medical information and avoiding patients to identify themselves with fellow-
sufferers who are doing worse, and, instead, identifying themselves with those who 
are doing better, were significant contributors to both better ability to cope with the 
unpleasant aspects of the underlying condition and better self-perceived quality of 
life as described in chapter 7. However, we don’t know whether we can improve 
QOL by increasing patients’ ability to cope. In addition, gender and psychic tension 
have been recognized as important determinants of QOL in cardiac patients. . The 
objective of chapter 8 is to assess two questions (1) whether we can improve QOL 
by increasing the patients’ ability to cope with the unpleasant aspects of a possible 
underlying heart condition, (2) whether gender and level of psychic tension interact 
or act independently. For that purpose we study 38 patients who are on the waiting 
list for coronary angiography. All of the patients are to be assessed by test 
batteries consisting of validated questionnaires.  
 
 
       





Chapter 9 concerns an early discharge protocol after primary angioplasty for acute 
myocardial infarction and focuses on feasibility and QOL. At our hospital we 
described an easy and practical score for early risk stratification in patients with 
ST-segment elevation treated with primary angioplasty. This score reliably 
identifies a large group of patients at very low risk, who may safely be discharged 
early after primary angioplasty. The score is based on coronary anatomy and flow 
parameters and can be applied immediately after the angioplasty. As a 
consequence, we developed a study that evaluates a short-stay protocol after 
myocardial infarction and primary angioplasty in a selected low-risk patient 
population. This protocol includes intensive out-patient follow up and cardiac 
rehabilitation for secondary prevention therapies. The objective of this chapter is to 
investigate the feasibility of the short-stay protocol after myocardial infarction and 
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Measurement of quality of life (QOL) as an indicator of health outcome has become 
increasingly important for patients with coronary artery disease (CAD), where the 
goal of treatment is not only to improve prognosis, but also to relieve symptoms 
and improve function 1,2 . Recent research has demonstrated that variables other 
than disease symptoms and pain are more important to patients for their quality of 
life. In particular, areas such as patients’ physical performance and psychological 
and social functioning have been recognized as important determinants. Also 
burden of symptoms and perceptions of well-being must be considered. Nitrates 
can effectively control symptoms of angina pectoris and have been demonstrated 
to reduce mortality in patients with acute myocardial infarction 3,4 . Based on the 
results of the GISSI-3 5 and the ISIS-4 6 studies, it is clear that nitrates can be 
safely used for long-term treatment. However, little is known about their net effects 
on current health-related QOL indices. Nitrates can be effectively applied for 
controlling symptoms of angina pectoris not only in patients with significant 
coronary artery disease but also in patients with other forms of ischemia, such as 
variant angina 7 and microvascular dysfunction 8. They have also been 
demonstrated to increase angina-free walking 9 and to decrease exercise-induced 
ischemia 10. A major problem with chronic treatment is nitrate tolerance which is 
probably caused by GTP-depletion in the vascular smooth muscle cells 11 , rather 
than some sort of receptor-mediated mechanism. Although it soon develops during 
continued therapy (limiting the usefulness of continued therapy), it can be 
prevented by asymmetric dosage regimens (e.g., b.i.d. therapy at 7 a.m. and noon 
or once-daily controlled release). Although these regimens do not provide 24 hour 
antianginal and anti-ischemic effects, they do give a sustained increase in exercise 
tolerance during the first part of the day with its circadian peak frequencies of 
anginal attacks 12,13, and, thus, have become a widely accepted approach 14,15,16. 
So far, little is known about the net effects of these regimens on current health 
related quality of life indices. This question is particularly relevant because these 
compounds produce significant adverse effects such as headache, hypotension, 
and reflex tachycardia 17.  
 
 
       





In 1985, isosorbide mononitrate (ISMN) in a once daily 30% immediate-release 
plus 70% sustained - release (IR-SR) formulation was introduced 18. It offered a 
number of theoretical advantages over conventional isosorbide mononitrate or 
dinitrate when immediately administered on arising 19. 
Isosorbide mononitrate provided better bioavailability than isosorbide dinitrate 
because it had no first-pass metabolism therefore it might be more effective in 
preventing drug tolerance than multiple-dose regimens given throughout the day. 
In addition, once-daily instead of multiple-dose therapy might be more convenient 
for individual patients and might therefore provide better patient compliance. 
The immediate-release component of the preparation might better protect patients 
from their circadian peak frequencies of angina pectoris early in the morning. 
 
Beneficial effects of nitrates 
The pharmacological effects of the organic nitrates depend on the underlying 
pathophysiological mechanisms leading to ischemic heart disease (table 1). 
Although early in the development of coronary atherosclerosis the effects of 
endothelium-dependent vasodilators such as acetylcholine and ATP are usually 
impaired, the endothelium-independent vasodilator effects of nitrates remain 




Beneficial effects of nitrates 
1.  Vasodilatation of coronary arteries 
2.  Reduction of preload and afterload on the heart 
3.  Redistribution of flow to vulnerable subendocardial areas 
4.  Beneficial effect in hypertensive crisis 
5.  Beneficial effect in adult respiratory distress syndrome 
6.  Reduction of remodeling 
7.  Blockade of platelet aggregation 
8.  Blockade of leukocyte adhesion to the vascular endothelium 
9.  Protection of endothelial cells from oxidative stress 
10. Antagonism of LDL oxidation 
 
 
       





However, with advanced coronary atherosclerosis the development of 
atheromatous plaques results in narrowing of lumen and restricted blood flow. The 
peripheral effects of nitrates may become more important. Nitrates produce a 
vasodilatation of the venous vasculature. Dilatation of venous capacitance vessels 
diminishes venous return to the heart, reducing diastolic volume and pressure. This 
decreases diastolic wall tension, one of the contributors to the oxygen demand of 
the heart. Thus, by decreasing preload on the heart, the oxygen needs of the heart 
diminish. Other effects of nitroglycerin administration also contribute to its 
beneficial effect in angina. Nitrates cause relaxation of resistance vessels, which 
decreases afterload placed on the heart. Reducing afterload decreases oxygen 
demands of the heart, just as reducing preload does. The nitrate effect on 
resistance arteries generally requires higher concentrations than those needed for 
venodilatation. Another feature of organic nitrate action in angina pectoris is 
redistribution of blood flow to the subendocardial areas of the heart, which are 
especially vulnerable to ischemia. By decreasing preload, nitrates reduce 
ventricular filling pressure and increase the time available for endocardial 
perfusion. In management of angina pectoris caused by coronary artery spasm, the 
organic nitrates, in addition to effects described above, are useful because of 
dilatation of constricted coronary vessels. We should add that these beneficial 
effects of nitrates are not necessarily restricted to angina pectoris, but may occur in 
any form or expression of heart disease (e.g. different forms of heart failure) 24. 
Hypertensive crisis and adult respiratory distress syndrome are noncardiac 
conditions frequently accompanied by heart failure, pulmonary oedema, or angina 
pectoris and infarction. Nitroglycerin has been unequivocally shown to influence 
these conditions beneficially and to perform better than nifedipine for that purpose 
25,26,27.  
 
Newly recognized beneficial effects of nitrates 
The pharmacological action of nitrovasodilators appears to be quite similar to that 
of endothelium derived relaxing factor (EDRF). EDRF is formed in and released 
from endothelial cells of blood vessels and the heart, and has been shown to be 
 
 
       





nitric oxide (NO) 28. Vasodilator substances such as acetylcholine, histamine, 
bradykinin, and adenosine triphosphate act on endothelial cells at their respective 
receptors to release NO, which subsequently diffuses into the vascular and cardiac 
smooth muscle cells. It activates cGMP- dependent protein kinase through the 
second messenger cGMP. This enzyme promotes relaxation of the contractile ele-
ments of the cell in several ways, including limiting Ca2+ entry through channels 
and a direct decrease in the sensitivity of contractile proteins to Ca2+. The 
modification of intracellular calcium levels seems to be the mode of action of the 
vasoconstrictor compounds norepinephrine, angiotensin II, and serotonin, although 
a different second messenger (i.e.,IP3) is involved. Recent research has also 
indicated that these vasoconstrictors stimulate growth factors ( i.e., cytokines, 
vascular endothelial growth factor, insulin, etc.), causing proliferation of fibroblasts, 
proliferative angiogenesis, vascular muscle cell hypertrophy, apoptosis 
(programmed cell death) of hypertrophied cells, and atherogenesis. Such effects 
are currently considered a major mechanism of left ventricular hypertrophy in 
hypertension and/or remodelling in ischemic heart disease. Unlike these 
vasoconstrictors, the vasodilator NO inhibits the proliferation of vascular smooth 
muscle cells 29,30 which may contribute to the regression of hypertrophy in such 
conditions similarly to the regression induced by ACE-inhibitors. However, 
prospective studies in man are still lacking. Other possibly beneficial effects of NO 
and its donors have been recognized. NO-donors are not only vasodilators, but 
also block platelet aggregation, probably by preventing the stimulation of 
thrombocytic soluble guanylate cyclase 31. Nitrates, in combination with 
prostacyclin or its analogues, have, therefore, been proposed as a useful 
antithrombotic therapy 32,33. 
A number of potentially beneficial effects of nitrates have been attributed to their 
capability to scavenge superoxide. First, they inhibit monocyte and macrophage 
adhesion to vascular endothelial cells, presumably by antagonizing the oxidation of 
the lipid cell membrane which triggers the expression of adhesion molecules by 
endothelial cells in vitro and in vivo 34,35 . Second, they protect the endothelium 
from oxidative stress, a term frequently used to refer to oxidative damage of DNA 
 
 
       





and other tissues of the cell leading to cell dysfunction, and ultimately apoptosis 
36,37,38 . Third, they inhibit the 15-lipoxygenase-mediated oxidation of LDL, which is 
considered an important factor early in the pathogenesis of atherosclerosis 34,39 .  
 
Harmful effects of nitrates 
Despite the growing literature attesting to the beneficial effects of NO-donors, other 
reports have suggested that NO has harmful properties as well. First, it may cause 
severe hypotension and blood flow abnormalities. Second, a rebound hypertension 
as well as rebound pulmonary hypertension after withdrawal has been reported 40. 
Third, it contributes to a catecholamine hyporesponsiveness of the vasculature 41. 
Fourth, it stimulates negative inotropic cytokines such as TNF, giving rise to 
myocardial depression 42 . Reversible myocardial depression following reperfusion 
of ischemic myocardium was documented in patients following myocardial 
infarction, cardiopulmonary bypass, thrombolytic therapy and coronary angioplasty 
43,44. The condition was associated with increased levels of NO products, and is 
currently referred to as the stunned myocardium, the mechanism of which was 
presumed to be cytokine-stimulated and NO-mediated 45. Recent research 
indicates that rather than NO itself the reaction product of NO with superoxide, 
peroxynitrite, is responsible for the delayed reversibility of cardiac muscle 
mitochondrial dysfunction, an effect which is prevented by the free radical 
scavenger urate if present in the blood at physiological levels 36,46. So, patients with 
a stunned myocardium may actually benefit from withdrawal of uricosuric 
compounds, and NO donors may be continued. Fifth, high concentrations of NO 
have been shown to disrupt metabolism, damage DNA, and cause cell death, 
suggesting that this free radical might cause direct tissue injury 47. Nitroglycerine 
intravenously administered in high dosages may give rise to the formation of toxic 
nitrites which in turn can oxidize the iron of hemoglobin converting it to 
methemoglobin. Also, they may give rise to neural toxicity as well as 
carcinogenity48.  
Clearly, NO does more than just cause vasodilatation, and the precise role in 
humans has not been fully established. Even so, the balance of arguments is 
 
 
       





currently in its favour. Also with usual dosages (e.g., 5-isosorbide mono- or 
dinitrate in a dosage of 15-120 mg daily 14) serious side effects and toxicity are 
rarely encountered in everyday cardiology practice.  
 
Long term efficacy, side effects and quality of life of isosorbide mononitrate 
IR-SR formulation 
Efficacy 
It is obvious that nitrates can be used safely for long-term treatment. However, little 
is known about long term efficacy, side effects and quality of life during continued 
treatment. Two large, open label studies recently completed addressed these 
issues 49,50. A total of 1350 patients with stable angina pectoris were treated for 
three months with conventional ISMN/ISDN 10-20 mg twice or three times daily, 
and subsequently, for the same period with once-daily 50 mg IR-SR formulation 49. 
A total of 1212 patients could be evaluated after six months. Not only did patients 
experience a 22.2% (p=0.03) reduction of anginal attack frequency during the 
second period, but also drug compliance improved by 23.8% (p=0.02). The 
investigators subsequently tested the hypothesis that 100 mg IR-SR formulation 
may perform even better than 50 mg; they used the same study design for 
assessment. In 505 patients with stable angina pectoris, 100 mg IR-SR for three 
months produced a further 13.9% (p=0.001) and 2% (p=0.01) further improvement 
of patient compliance. The better compliance may explain part of the improved 
efficacy, but not all of it. Table 2 shows a comparison of multiple dose and 100 mg 
IR-SR formulation as calculated by the product of odds ratios of ‘multiple dose/50 
mg IR-SR’ and ’50 mg IR-SR/100 mg IR-SR’. Although this is an extrapolation, it 
may be acceptably valid since the procedure is straightforward and the data are 
from similar institutions and investigators 19. The largely unchanged quantity of 
sublingual nitroglycerin required in the studies was consistent with the situation in 




       






Drug tolerance did not develop after 50-100 mg IR-SR formulation, patients’ self-
assessed rating scores continued to improve rather than to deteriorate on higher 
dosages 49,50. Drug tolerance did not develop in three more open label trials from 
other groups (n=30-45 patients per study) 51,52,53 after 6 to 13 months of treatment, 
whereas improvement of anginal attack frequencies, and level of ST-depression 
during angina were similar to those in the above two studies. Except for headache, 
other side effects of 50-100 mg isosorbide mononitrate IR-SR formulation were 
rare and negligible. Headache, nonetheless, occurred as frequently as with multiple 
ISMN/ISDN dosages in between 41 and 67% of the patients 49,50. Particularly 
during the first weeks of treatment, headache is commonly reported. For example, 
in a six-week double-blind, parallel-group study, both IR-SR formulation 50-100 mg 
once daily and conventional isosorbide mononitrate 80-120 mg daily necessitated 
drug withdrawal in up to 17% of the patients 54.  
 
TABLE 2.   Odds ratios* of symptoms and Quality-of-life indices of patients with stable angina 
pectoris treated with 50 mg and 100 mg isosorbide mononitrate IR-SR formulation once daily vs. 




Multiple dose/   
50 mg IR-SR    p value  
Odds ratios  
Multiple dose/ 
100 mg IR-SR 
 p value 
Mobility index 0.83 <0.001 0.69 <0.001 
Side effect index 0.99 0.85 0.96 <0.001 
Anginal pain index 0.64 <0.001 0.56 <0.001 
Anginal pain index 8-10 hr am 0.65 0.006   
Psychological well-being index 0.87 0.036 0.75 <0.001 
Patient compliance 0.50 <0.001 0.48 <0.001 
Sublingual nitroglycerin consumption 0.94 0.68   
 
*odds ratios = mean scores during multiple-dose conventional isosorbide mononitrate/mean scores 




       





In a double-blind study by our group, 55 it was demonstrated that this effect can be 
avoided to a great extent by starting with isosorbide mononitrate dosages as low as 
25-30 mg daily. Such dosages of IR-SR formulation have become available 
recently.  
 
Quality of life  
Important quality of life indices were also addressed in two studies 49,50. A once-
daily dose of 50 mg IR-SR for three months gave significantly better scores than 
multiple-dose conventional ISMN/ISDN: mobility index improved 5.5% (p=0.04), 
and psychological well-being index improved 5.6% (p=0.04). In addition, 100 mg 
IR-SR once daily for three months gave better scores than 50 mg IR-SR: 20.3% 
(p<0.001) and 5.8% (p<0.001) further improvement of mobility and psychological 
well-being indices. Table 2 shows the extrapolated odds ratios of multiple dose/100 
mg IR-SR calculated by the products of odds ratios ‘multiple dose/50 mg IR-SR’ 
and ‘50 mg IR-SR/100 mg IR-SR’ from the two separate studies 49,50. Although 
based on extrapolation, these estimates suggest that in particular high-dose IR-SR 
formulation may provide a considerable further improvement of mobility and 
psychological well being. 
 
Discussion 
Unfortunately, none of the long term studies on IR-SR isosorbide mononitrate 
formulation were blinded, and so the risk of placebo effects partly explaining the 
results can not fully be ruled out. A current problem with designing long-term nitrate 
studies is that it is ethically increasingly difficult to replace nitrate therapy with 
placebo in symptomatic patients even though improved survival with long-term 
nitrate therapy has not been unequivocally proven. At the least, the results of the 
large QOL studies 5,6 do not support the presence of major placebo effects in the 
data, since important changes occurred in the mobility and psychological well-
being indices rather than in the anginal pain and side effect indices, which are 
generally particularly susceptible to placebo effects in QOL assessments 2. 
 
 
       





The primary approach of patients with angina pectoris must involve the adequate 
treatment of their coronary condition, e.g. by coronary bypass surgery or 
percutaneous coronary angioplasty, rather than treatment with nitrates. If patients 
remain symptomatic despite adequate treatment, or if they have to wait for such 
interventions or do not qualify for them for any other reason, nitrates as well as 
other antianginal drugs should be considered. Parker and Parker 56 recently 
reviewed prescribing patterns regarding current nitrate therapy and recommended 
that (1) slow-release nitrates, rather than beta-blockers or calcium channel 
blockers, be given as an initial preventive therapy for stable angina pectoris, 
particularly in patients who respond well to sublingual nitroglycerin; and (2) beta-
blockers or calcium channel blockers be given as initial therapy in patients with 
coexistent hypertension and/or a history of MI. We suggest that nitrates be 
routinely added in the latter category, given their apparent improvement of various 
QOL indices. A particularly interesting aspect of treatment with nitrates, although 
predominantly of a theoretical nature so far, is their potential to offer more than just 
symptomatic treatment 17. Nitrates, being NO donors, have been thought to reduce 
remodelling 29, blockade platelet aggregation 30, and adhesion receptors of 
vascular endothelial cells 35, and probably most importantly to protect the 
endothelium from oxidative stress by scavenging superoxide 38. Angiotensine II is 
an important producer of oxygen free radicals and it is this property that is largely 
held responsible for the deleterious effects of the compound on the myocardium as 
well as vascular endothelium 57. A supposed antagonistic effect between NO and 
angiotensin II on oxygen free radicals is a plausible hypothesis 58 to explain the 
widely published beneficial effect of ACE inhibitors on the efficacy of nitrate 
treatment 59. The risk of hypotension with nitrates is small because the compound 
has little influence on systemic blood pressure and the same applies with the IR-
SR formulation. The risk of methaemoglobin due to overdosing 14 should be better 
prevented by a once-daily IR-SR formulation with predictable pharmacokinetic 




       





We conclude that IR-SR isosorbide mononitrate has a rapid onset of action, is 
clinically efficient, and provides better quality of life than the conventional 
ISMN/ISDN. Tolerance with continued use of the formulation has not yet been 
reported. Long-term efficacy data both of isosorbide mononitrate IR-SR and 
conventional ISMN/ISDN are limited so far. A large study in patients with angina 
pectoris (International Quality Of Life assessment of patients with Angina pectoris 
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Background: Once-daily dosage regimens of isosorbide mononitrate provide better 
antianginal efficacy and quality of life in patients with stable angina pectoris than 
does the daily administration of multiple small doses of the compound. It is 
unknown whether certain patient characteristics contribute to this better benefit.  
Objective: To determine independent factors contributing to this better benefit. 
Multiple linear regression analysis was performed of a self-controlled study of 1350 
patients with stable angina pectoris. Quality of life was assessed by the Marquis-
questionnaire for patients with angina and included the domains immobility, pain, 
and psychological distress. Individual scores were calculated as the pooled sums 
of the domain scores and were expressed on an ordinal scale of 10.  
Results: Age did not influence the better benefit. Neither did gender, rhythmic 
disturbances, peripheral artery disease, or the concomitant use of calcium channel 
blockers or beta-blockers. New York Heart Association angina classification was an 
independent variable: patients with a class I or II benefited less than did patients 
with class III or IV (P=0.02). Obese patients as well as hypertensive patients 
benefited less (P=0.04 and 0.02), and smokers tended to benefit less (P=0.08). In 
contrast, cholesterolemia and diabetes mellitus improved the beneficial effect of 
nitrates on quality of life (P= 0.03 and 0.05).   
Conclusions: Patients with severe angina pectoris benefit better from nitrate 
therapy than do patients with New York Heart Association class I-II. Also, patients 
with coronary artery disease and concomitant diabetes mellitus or cholesterolemia 
may better benefit from nitric oxide-donor therapy than patients without such 
concomitant conditions do. In contrast, patients with concomitant obesitas, 






       






Asymmetric dosage regimens of isosorbide mononitrate (ISMN) are more effective 
antianginal treatments than daily administration of multiple small doses of the 
compound, because nitrate tolerance is less likely to develop 1. Nitrates are nitric 
oxide (NO) donors. Patients with coronary artery disease (CAD) may or may not 
have endothelial dysfunction of coronary arteries and, thus, dysfunctional 
endogenous nitric oxide production 2,3. Patients with dysfunctional endogenous NO 
production may better benefit from effective nitrate treatment than do others. 
However, this has not been tested. Patients with diabetes mellitus 4, hypertension 
5, smoking 6, cholesterolemia 7, are particularly at risk of early endothelial 
dysfunction. The present paper tries to test the hypothesis that such patients might 
better benefit from effective NO donor therapy than do patients without such 
concomitant conditions.  
For this purpose we performed a multiple linear regression analysis of a 
comparative study of 1,350 patients with stable angina pectoris (SAP) treated for 6 
months with either 50 mg ISMN administered orally at 8 hours AM (asymmetric 
dosage regimen) or with standard multiple daily oral doses of the compound. In the 
univariate analysis of this study 8 the former modality improved New York Heart 
Association (NYHA) angina class and improved various quality of life indices 
compared to the latter modality. The objectives of the current study was to assess 
whether the presence of concomitant conditions, particularly those associated with 
early endothelial dysfunction, are independent determinants of the better benefit 
from effective nitrate therapy.   
 
Subjects, Material and Methods 
When the size of a study permits, important demographic or baseline 
characteristics for example age, gender, and the severity of condition, can be 
studied for influencing efficacy response 9. Such analyses do not prove anything 
but may be helpful to refine questions for subsequent studies. Our intended 
treatment population consisted of 1,350 patients, which is large enough in size for 
such purposes. Patient characteristics are given in Table 1. 
 
 
         





TABLE 1.   Patient Characteristics of Intention to Treat Population (n=1350). 
 
 n (%) 
Male gender                                        848 (63) 
NYHA angina classification   
I    265 (20) 
II      849 (63) 
III 173 (13) 
IV   14 (1) 
Smokers   215 (16) 
Hypercholesterolemia 407 (30) 
Hypertension 400 (30) 
Diabetes mellitus                                   143 (11) 
Rhythm disturbances                           195 (14) 
Peripheral vascular condition                194 (14) 
 
NYHA= New York Heart Association 
 
All of these patients were treated for 3 months with ISMN immediate release 
multiple small daily doses and subsequently for another 3 months with 50 mg slow-
release formulation. Primary efficacy data were estimated as anginal pain indices 
and quality of life (QOL) indices using the QOL-questionnaire of patients with 
angina pectoris by Marquis 10 and included the domains of immobility, pain, and 
psychological distress. For the purpose of this study, overall QOL was calculated 
as the pooled sums of the domain scores, scored on an ordinal scale of 0 to 10, 
and expressed as odds ratios ( where the odds ratios are the mean scores during 
novel formulation divided by the mean scores during standard formulation doses). 
In brief, published results 8 show that the slow-release formulation of ISMN 
produced a 17% greater improvement in mobility, a 36% decrease of anginal pain 
index, a 35% greater reduction of anginal pain between the hours of 8 and 10 AM, 
a 13% greater improvement in psychological well-being, and a 50% greater 
improvement of patient compliance ( P values were between P=0.03 and <0.001). 
For the purpose of the multiple regression analysis, the summary odds ratios of 
QOL scores were added up and linearly transformed on a scale of 0 to 10, and 
subsequently used as dependent variable, otherwise called response variable. 
 
 
       





Independent variables, otherwise called explanatory variables, included the 
nominal variables, gender, presence of arrhythmias, peripheral vascular disease, 
co-medications, NYHA class, smoking, hypertension, diabetes, and the continuous 
variables, age, body mass, plasma cholesterol levels. We did not try stepwise 
exclusion of non-significant independent variables, because all of the variables 
included studied important demographic characteristics, that we considered it 
necessary to adjust for them even if not statistically significant. 
To test internal consistency and reliability of the data we used Cronbach’s alpha 11. 
SPSS statistical software was used to provide the best fit for the data as given, and 














where c is intercept and beta1, beta2, etc are the estimated slopes of the multiple 
linear regression equation. Regression coefficients were statistically tested with t-
tests, and a P value of at least 0.05 was considered statistically significant. In a 
multiple regression analysis the x-variables should not tend to be highly related to 
each other, because most of the variance in one x-variable can be accounted for 
by the other x-variable. This problem known as multicollinearity was assessed by a 
correlation matrix of the x-variables.  
 
Results 
Our intention-to-treat population consisted of 1,350 patients (mean age ± standard 
deviation: 68 ±10 years), which is large enough a size for the purpose of a multiple 
regression analysis. CAD was confirmed by coronary angiography in 999 of the 
patients and in 351 of the patients on clinical grounds. Additional patient 
characteristics were shown in Table 1. 
y = c + beta1.1 + beta2.2 +........beta12.12 
           
Odds ratio of quality of life scores  = c + beta1(presence of hypertension)  
+ beta2 (presence of diabetes) + …… beta12 ( hypercholesterolemia) 
 
 
       





Table 2 gives a correlation matrix of the x-variables to be entered in the multiple 
regression analysis. As expected, there was a generally weak and insignificant 
correlation as estimated by Pearson correlation coefficient between the x-variables 
to be entered. Only the correlation between age and other variables appeared to 
be borderline significant, but in none of the comparisons adjustments for 
multicollinearity were required (correlation coefficient > 0.9).   
 
TABLE 2.   Correlation between factors contributing to benefit of nitrate therapy (Pearson 
correlation coefficients of >0.07 or <-0.07 were consistent with a P-value <0.05). 
 
 Age Gender Rhythm Vascdis Ccb Bb NYHA Smoke Bmi Chol hypt 
Gender 0.19           
Rhythm 0.12 ns          
Vasc dis 0.14 ns ns         
Ccb 0.24 ns 0.07 ns        
Bb 0.33 ns ns ns 0.07       
NYHA 0.22 ns ns 0.07 0.07 ns      
Smoking -0.12 ns 0.09 0.07 0.08 ns 0.07     
Bmi 0.13 ns ns ns ns 0.10 ns -0.07    
Chol 0.15 ns ns 0.12 0.09 ns ns 0.08 0.09   
Hypt 0.09 ns 0.08 ns 0.10 0.09 0.07 0.09 0.09 0.07  
Diabetes 0.12 ns 0.09 0.10 ns 0.08 0.08 ns 0.11 0.12 0.10 
 
Vasc dis= peripheral vascular disease; Ccb= concomitant calcium channel blocker therapy; Bb= 
concomitant beta-blocker therapy; Bmi= body mass index; Hypt= hypertension; ns= not statistically 
significantly correlated. 
 
Table 3 gives the results of the multiple linear regression analysis. Age, obviously, 
did not influence the beneficial effect of nitrate therapy on QOL in our material. 
Neither did gender, rhythmic disturbances, peripheral artery disease, or the 
concomitant use of calcium channel blockers or beta-blockers. The NYHA angina 
classification, however, did influence the QOL outcome. Patients with a NYHA 
class I or II benefited less from nitrate therapy than did patients with NYHA class III 
or IV (P=0.02). Smokers tended to benefit less (P=0.08), and obese patients 
benefited less (P=0.04). In contrast, cholesterolemia and diabetes mellitus 
 
 
       





improved the effect of nitrates on QOL (P=0.03 and P=0.02). Hypertension, finally, 
benefited again less (P=0.05).  
 
TABLE 3.   Regression Coefficients and Standard Errors for a Multiple Linear Regression of 










Age -0.03 -0.11 to 0.05 0.8 ns 
Gender 0.01 -0.09 to 0.11 0.5 ns 
Rhythm disturbances -0.04 -0.12 to 0.04 1.0 ns 
Peripheral vascular 
disease 
-0.00 -0.02 to 0.02 0.1 ns 
Calcium channel  
blockers 
0.00 -0.02 to 0.02 0.1 ns 
Beta blockers 0.03 -0.05 to 0.11 0.7 ns 
NYHA-classification  
I or II 
-0.08 -0.14 to 0.02 2.3 0.02 
Smoking -0.06 -0.14 to 0.02 1.6 0.08 
Body mass index -0.07 -0.13 to –0.01 2.1 0.04 
Cholesterolemia 0.07 0.01 to 0.10 2.2 0.03 
Hypertension -0.08 -0.14 to –0.02 2.3 0.02 
Diabetes mellitus 0.06 0.00 to 0.12 2.0 0.05 
 
NYHA= New York Heart Association; CI =confidence interval; ns= not statistically significant. 
 
Discussion 
The current study is a post-hoc analysis of a previously published 8 sequential 
study  with the same order of treatments for all of the patients. One may speculate 
that carry-over effect may have influenced the treatment comparison. However, 
since the, presumably, more effective treatment was given after the less effective 
treatment, this risk may be less important.  
Obviously, the levels of significance in the multiple regression analysis were not 
very low (between P=0.02 and 0.08), and so the chance of type I errors of finding a 
difference where there is none, cannot be ruled out. However, since the overriding 
 
 
       





interest of our regression modelling was of exploratory nature, we decided to be 
liberal about including covariates in the model, at the risk of encountering some 
type I errors. Some statisticians even recommend to use P-values as low as 0.10 
or even 0.20 for purpose of these kinds of analyses 9.    
The current study, nonetheless, shows a significantly better benefit from effective 
nitrate therapy in patients with NYHA class III-IV angina pectoris than in patients 
with NYHA class I-II. Obviously, the more symptomatic the patients, the better the 
benefit from this symptomatic therapy. Second, we found that concomitant diabetes 
and cholesterolemia were associated with a better benefit. In diabetic and 
cholesterolemic patients with 4,5 or without 12,13,14,15,16 CAD, endothelial dysfunction, 
and, thus, dysfunctional endogenous NO production develops early. Although 
matter of speculation, the above mechanism would nicely explain the better benefit 
from NO donor therapy in these categories of patients in our study. Endothelial 
dysfunction and, thus, dysfunctional endogenous NO production is currently given 
particular emphasis in the pathogenesis of CAD in diabetic patients. Diabetes 
mellitus produces a two to threefold increased risk of coronary artery disease, and 
a twofold increased cardiac mortality 4. Such greater risk could not be attributed to 
the presence of the three classic risk factors including smoking, hypertension, 
cholesterolemia: e.g., the large GISSI 2 17, CONSENSUS II 18, GUSTO I 19, CORE 
20, TRACE II 20 studies showed no difference in presence of such risk factors 
between diabetic and non-diabetic patients. Thrombolytic therapy, aspirin, ACE-
inhibitors, and beta-blockers in diabetic patients were not particularly efficacious in 
diabetic patients in these studies. According to our study, this may be different with 
NO donor therapy: at least NO donors were particularly efficacious for symptomatic 
treatment of diabetic patients with CAD in our hands. 
In contrast, hypertension and smoking, decreased or tended to decrease the 
benefit from effective nitrate therapy in our study. We have no obvious explanation 
for this unexpected finding, but the anginal complaints in such patients may 
sometimes have another mechanism than endothelial dysfunction. E.g., patients 
with hypertension may have increased peripheral resistance 5, and this may 
contribute to reduced exercise tolerance and angina-like complaints. Also nicotine 
 
 
       





causes vasoconstriction of resistance arteries 6, and so, also in this category of 
patients, increased peripheral resistance may contribute to such symptoms. 
Increased peripheral resistance is negligibly influenced by NO donors 3. It would 
explain why such patients benefit less from nitrate therapy. Finally, the patients 
with the highest body mass indices in our study, unlike healthy subjects, benefited 
less in our study from nitrate therapy than did their low body mass index 
counterparts. It can be explained as follows. Patients with mobility reducing obesity 
and a low NYHA classification-score have little anginal symptoms from the very 
start, and so, treatment may contribute little to their improvement of QOL. 
 
Conclusions 
The current study suggests that patients with angina NYHA class III-IV benefit 
better from effective nitrate therapy than do patients with angina NYHA class I-II. 
Patients with CAD and concomitant diabetes mellitus or cholesterolemia may better 
benefit from effective nitrate therapy than do patients without such concomitant 
conditions. Patients with smoking, high body mass index or hypertension may 
benefit less. The data are from a post-hoc study, and they are, therefore, 
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Background: Chronic nitrate therapy administered once daily may be more 
convenient to patients and may better protect them from nitrate tolerance than 
multiple dose nitrate therapy. This is supported by a large Dutch study of patients 
with stable angina pectoris showing not only a better anginal class and patient 
compliance but also a better quality of life (QOL). Recent research has 
demonstrated that patients' self-rated satisfaction with disease state is an important 
additional indicator of QOL in these patients, and that chronic nitrate therapy may 
also benefit heart failure class in some of these patients. 
Objective: To assess whether the Dutch data could be generalized across nations 
and times. To assess the effects on patients' satisfaction with disease state and on 
heart failure class. 
Methods: Patients from hospitals in Germany, Portugal, and the Czech Republic 
were treated for 3 months with 2-4 times daily 10-20 mg isosorbide 
mononitrate/dinitrate and, subsequently, with once daily 50-120 mg isosorbide 
mononitrate/dinitrate for three more months. A QOL questionnaire, based on 
Wiklund's exercise tolerance index, Stewart's Short Form Questionnaire, and 
Dupuy's psychological well-being index, was completed after 3 and 6 month 
treatment. In addition, patients' self-rated satisfaction with the current disease 
state, their treatment preference, and their New York Heart Association (NYHA) 
anginal and heart failure class were assessed twice. 
Results: Of the 1045 patients included, 1010 (97%) completed the study. After 
three months of once-daily nitrate therapy the QOL-scores showed a significantly 
better improvement in all of the domains addressed, than did multiple daily dose 
treatment (p<0.0001). In addition, anginal and heart failure classes improved 
significantly better(p<0.0001). So did patient compliance as estimated by the 
percentages of patients forgetting to take their medication (59.6 versus 42.2%, 
p<0.0001), patients' self-rated satisfaction (30.5 versus 10.1%, p<0.0001), and 





       





Conclusions: Once-daily nitrate treatment provides better NYHA anginal class, 
patient compliance, and QOL than does multiple daily dose treatment. These better 
benefits can be observed across nations and times. In addition to QOL indexes, 
patients' self-rated satisfaction with disease state improved better, and so did 




       






Chronic nitrate therapy administered once-daily may be more convenient to 
patients and may better protect them from nitrate tolerance than multiple daily dose 
nitrate therapy. This is supported by a large Dutch study of patients with stable 
angina pectoris: once-daily therapy improved not only New York Heart Association 
(NYHA) anginal class and patient compliance but also quality of life (QOL) indexes 
significantly better 1. Recent research has demonstrated that patients' self-rated 
satisfaction with disease state is an important indicator of QOL in this category of 
patients, in addition to the traditional QOL indexes like physical, social, and 
psychological indexes 2,3,4. Also, it has been recently demonstrated by our group 
that many patients with stable angina pectoris have some degree of heart failure, 
and that not only their anginal class but also their heart failure class benefits from 
chronic nitrate treatment 5.  
The primary objective of the current study was to assess whether the above Dutch 
study was reproducible, and could be generalized across nations / populations and 
across times. The secondary objective was to assess the effects of treatment 
modality on patients' satisfaction with their disease state, and on their NYHA heart 
failure class. 
In order to reduce between subject variability of symptoms, and, thus, enhance the 
sensitivity of testing, a self-controlled study design was chosen with all of the 
patients starting on multiple dose nitrate therapy, and, after 3 months switching to 
once-daily nitrate therapy for three more months.  
Patients were recruited from hospitals in Germany, Portugal, and the Czech 
Republic.  
 
Patients and methods 
Design 
Because equivalent treatments were compared, the possibility of testing not only 
differences but also bioequivalence was included. For that purpose a statistically 
powerful comparison was required. A self-controlled comparison would provide 
adequate power. Based on prior data1 treatment was expected to improve QOL 
 
 
       





indexes by 7%. Under the assumption of standard deviations of 25% and a 
correlation of + 0.6, the study would have to include 1000 patients. A crossover 
design would have enabled to randomize patients. However, such a design is at 
risk of psychological and physical carryover effects, particularly if a more 
efficacious is given prior to a less efficacious one. We, therefore decided to use a 
simple self-controlled design with all of the starting on the, presumably less 
efficacious, multiple dose nitrate therapy changing over after three months to the, 
presumably more efficacious, once daily treatment. This design closely met the rest 
of our criteria including those involving medical ethics and recruitment methods. 
Multiple dose nitrate therapy consisted of 2 to 4 times daily 10-20 mg of isosorbide 
mononitrate or isosorbide dinitrate while once-daily nitrate therapy consisted of 50 
mg of isosorbide mononitrate in Portugal and the Czech Republic and of 120 mg of 
isosorbide dinitrate in Germany.  
Quality of life was assessed after three months of multiple dose and after three 
months of once daily nitrate therapy by self-administered questionnaires. In 
addition, patients' satisfaction with the current disease state and treatment 
preference was assessed. NYHA classification for coronary heart disease and 
congestive heart failure as well as information on nitrate therapy were documented 
by the physicians. A placebo control was not included in the protocol because it 
was not considered ethical to withdraw symptomatic patients from active therapy.  
 
Patients 
Out-patients from hospitals in three European community countries were sampled. 
Inclusion criteria included: presence of coronary artery disease documented either 
by coronary arteriogram and / or by myocardial infarction or by clinical signs only, 
presence of symptoms of stable angina pectoris treated by beta-blockers and / or 
calcium channel blockers and / or sublingual nitrates ad libitum so far. Exclusion 
criteria included the presence of serious diseases other than coronary heart 
disease, hospitalization within one month of enrolment especially for myocardial 
infarction, coronary bypass surgery or angioplasty. An adequate knowledge of the 
language was required.  
 
 
       






Methods of evaluation 
Patients completed twice a validated 24-item quality of life questionnaire in local 
language. The items of the questionnaire were based on the Short-Form 36 
questionnaire of Stewart 6 , the exercise tolerance index of Wiklund 7, the pain 
index of Marquis 2 for patients with angina, the psychological well being index of 
Dupuy 8, and the distress scale of Testa and Simonson 3. The following domains 
were assessed: functional dependence (8 items), side effects (7 items), anginal 
pain (5 items), and psychological distress (4 items). For each item the individual 
response was scored on a 5-point scale from 0 to 4. The sum of scores was used 
for further evaluation. Higher scores indicated worse quality of life. In addition, 
patients' satisfaction with regard to the current disease state (2 items) and the 
patients' own estimation of their compliance (2 items) were assessed on 5-point 
scales. The first and second QOL questionnaires were identical except for an 
additional question in the second form requesting the patient to give his/her 
preference either for the multiple dose or for the once-daily regimen.  
On an additional form physicians reported the individual patient characteristics 
such as demographics, eligibility criteria, cardiovascular risk factors, cardiac 
history, concomitant therapies, and the current NYHA anginal and heart failure 
class. In case the patient did not continue the study the reasons for withdrawal 
were documented. Also information on adverse events was collected.  
 
Statistical analysis 
Qualitative characteristics were described by absolute and relative frequencies 
(percentages). Variables which could be observed after three and after 6 month 
treatment were cross-classified. Quantitative and the scored qualitative 
characteristics as well as the differences between before and after change-over of 
therapies were described by mean, standard deviation, median, lower and upper 
quartile, minimum, and maximum. For statistical analysis were used two-sided 
statistical tests: changes of the sum of scores were analyzed by paired t-tests, 
changes of frequencies regarding the qualitative characteristics Bowker's 
 
 
       





symmetry tests and McNemar's tests. 95% confidence intervals (95% CI) and 
standard deviations (SDs) are given, a p<0.05 was considered significant. 
 
Results 
1045 patients were enrolled at 200 centres. 1010 patients (96.6%) completed the 
study. The majority of patients was male. Age ranged from 34 to 100 years with a 
mean of 66.4 years. All of the patients suffered from coronary artery disease. 
Angina pectoris was classified as NYHA class II in the majority of patients (57.4%) 
and class III in 25.6% of all patients. For congestive heart failure NYHA class II was 
most frequent (37.1%), followed by class I (29.9%). Patient characteristics are 
given in table 1, NYHA classifications in table 2. The cardiovascular risk factors 
were typically those of this patient population. Hypertension was found in 64.0% 
(n=669), hyperlipidemia in 54.6% (n=571) of the patients. Familial coronary artery 
disease was present in 38.5% of the patients (n=402). According to their 
physicians 38.4% of the patients were obese (n=401) and 30.6% were smokers 
(n=320). A history of diabetes was given in 25.7% (n=268). 136 patients (13.0%) 
suffered from peripheral vascular problems. 
 
TABLE 1.   Patient characteristics. 
 
 Total Germany Portugal Czech Republic 
Centres (n) 200 132 65 3 
Patients (n) 1045 606 379 60 
Males (%) 64.4 64.7 63.6 66.7 
Age (years, mean  SD) 66.4  10.2 67.6  10.2 65.2  10.0 64.2  10.8 
Previous angiography (n) 300 (28.7%) 220 (36.6%) 62 (16.4%) 18 (30.0%) 
Previous MI (n) 271 (26.0%) 152 (25.1%) 95 (25.0%) 24 (40.0%) 
 




       






TABLE 2.   1045 patients suffered from angina, 833 in addition from congestive heart failure. The 













































NYHA = New York Heart Association 
 
Table 3 gives an overview of the results of the QOL assessments. After three 
month treatment with the once-daily nitrate regimen, improvements both of the 
average score sums and of the separate items of all of the domains were 
observed. No major differences between the countries were observed (country-
specific data not shown). For the domain "functional dependence" the overall score 
change was most pronounced by -4.3  0.2, followed by the change for the 
domains "anginal pain" by -2.4  0.1, "side effects" by -2.3  0.1, and 
"psychological distress" by -1.6  0.1, all of them highly significant at p<0.0001.  
 
TABLE 3.   Mean quality of life (QOL) scores. For functional dependence, side effects, anginal 
pain, and psychological distress maximal scores are respectively 40, 35, 25, and 20. Higher 
scores indicate worse QOL. 
 
 
95% CI = 95% confidence interval, SD = standard deviation 
Multiple dose Single dose 
Difference 
multiple - single dose   
mean ± SD mean ± SD mean  95% CI p 
Functional dependence 16.1 ± 6.5 11.8 ± 6.2 -4.3  -4.6 to -4.0 < 0.0001 
Side effects 11.6 ± 5.4 9.3 ± 5.1 -2.3  -2.5 to -2.0 < 0.0001 
Anginal pain 6.8 ± 4.2 4.4 ± 3.6 -2.4  -2.6 to -2.2 < 0.0001 
Psychological distress 8.6 ± 3.7 6.9 ± 3.7 -1.6  -1.8 to -1.5 < 0.0001 
 
 
       






p < 0.0001 
Figure 1 shows the effect of treatment on NYHA anginal and heart failure class. 
Once-daily nitrate regimen improved both of the classes in a highly significant 
manner (p<0.0001). Particularly, the percentages of patients in anginal class I 
raised from 16 to 45%, in heart failure class from 40 to 47%. Similar effects were 
observed in the data of the separate countries (country-specific data not shown). 
 
Figure 1a.   Improvement of New York Heart Association anginal class (based on 1045 patients, 
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Improvement of satisfaction with current disease state as estimated by the 
question: “If you had to live with your present heart problem, how satisfied would 
you then be?” is shown in Figure 2. Instead of add-up sums of scores, here 
separate scores for each point of the 5-point scale were assessed (% of patients). 
Obviously, many more patients were satisfied with single dose than they were with 
multiple dose. 
 
Figure 2.  Improvement of satisfaction with current disease state as estimated by the question: 
“If you had to live with your present heart problem, how satisfied would you then be?” Instead of 
add-up sums of scores, here separate scores for each point of the 5-point scale are given (% of 
patients).  
 
Patient compliance improved better with once daily nitrate (Figure 3) as estimated 
by a significantly lower percentage of patients forgetting to take their medication 
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p<0.05). 77.4% preferred once-daily to multiple dose for future treatment while only 
3.6% preferred the opposite (19% unknown). 
 
Figure 3.    Improvement of patient compliance, based on the question: "Do you forget to take 
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The current study shows that long-term once daily nitrate treatment provides a 
significantly better anginal class, patient compliance, and quality of life than does 
multiple dose nitrate treatment. These results are in line with the results of the 
Dutch study 1, and further support that once daily treatment is more convenient to 
patients and better protects them from nitrate tolerance. Also the present study 
shows that patients' self-rated satisfaction 2,3,4 with disease state, currently 
considered as the most important indicator of quality of life, is significantly higher 
with once daily than it is with multiple daily dose treatment. Finally, the data confirm 
not only that patients with stable angina pectoris often suffer from concomitant 
heart failure but also that the heart failure class is beneficially influenced by nitrate 
treatment, and significantly better so by a once daily than by a multiple daily dose 
regimen. 
Mc Nemar 
p < 0.0001 
 
 
       






The limitations of the current study include that it did not control carryover effects 
and time effects. However, carryover effects mainly occur if a more efficacious 
treatment is given prior to a less efficacious treatment 9 , while in our study the 
order of treatment was opposite. This was a study of patients with stable disease, 
and we presumed, therefore, that the risk of major time effects may be negligible. 
Another limitation of the study includes that it did not control placebo effects. 
Indeed, placebo effects may occur with quality of life assessments. However, this 
has been demonstrated to be particularly so in the physical symptom and pain 
domains, rather than in the functional dependence and distress domains 10,11. 
Moreover, it was not considered ethical to replace nitrate therapy with placebo in 
these symptomatic patients for such a long period of time. 
We conclude that once-daily nitrate treatment provides better NYHA anginal class, 
patient compliance, and QOL than does multiple daily dose treatment. These better 
benefits can be observed across nations and times. Not only traditional QOL 
indexes improved better, but also patients' self-rated satisfaction with disease 
state. So did NYHA heart failure class.  
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Background: In a retrospective study from the Dutch Mononitrate Quality of Life 
(DUMQOL) Study Group, the authors found that anginal patients with concomitant 
diabetes or hypercholesterolemia derived more benefit from changing over to a 
once-daily nitrate treatment regimen, than did anginal patients without.  
Objective: To assess this issue prospectively. 
Methods: In an open-label study patients with stable angina pectoris (SAP) from 
facilities in Germany, Portugal, and the Czech Republic were treated for 3 months 
with multiple daily dosages and subsequently for 3 more months with once daily 
isosorbide mono-/dinitrate (ISMN/DN). After the first and second 3 month period 
they were assessed by a validated QOL-battery including the domains, mobility, 
side-effect, life-satisfaction, anginal-pain, and psychological-distress.   
Results: In the 1045 patients who participated in the study mean summary domain-
scores varied from 5-16 points, score improvements from 1.6 to 4.3 points. In the 
patients with concomitant hypertension and the smokers domain-scores improved 
less than they did in the patients without, with differences in domain-score 
improvements up to 1.0 points (p<0.001), which is substantial considering the 
range of improvement being between 1.6 and 4.3 points. In the patients with 
diabetes mellitus or hypercholesterolemia a reversed pattern was observed with 
differences in domain-score improvements up to 0.4 points (p<0.05).  
Conclusions: Anginal patients with diabetes or hypercholesterolemia derived more 
benefit from a once-daily regimen of isosorbide mono/dinitrate than did patients 
without. Anginal patients with hypertension or smokers did less so. Differences in 






       






Once daily dosage regimens of isosorbide mononitrate/dinitrate (ISMN/ISDN) are 
more effective antianginal treatments than multiple daily dosages, because nitrate 
tolerance is less likely to develop.1 In a retrospective study the authors found that 
anginal patients with concomitant diabetes or hypercholesterolemia derived more 
benefit from changing over to a once daily regimen than did patients without.2 In 
contrast, anginal patients with concomitant hypertension or smokers derived less 
benefit.2 Retrospective studies are at risk of confounding and recall bias, and have 
to be confirmed by prospective data. The IQOLAN ( International Quality Of Life 
ANgina study)3 , an international survey with a focus on quality of life (QOL) in 
nitrate-treated patients with angina pectoris gave us the opportunity to assess this 
issue prospectively.  
Thus, we assumed that anginal patients with comorbidities may better benefit from 
a once daily dosage regimen than patients without. For that purpose we compared 
improvements of QOL after 3 month multiple dose and after 3 month once daily 
treatment in patients with and without comorbidities. For assessment a validated 




Out-patients were recruited from 200 facilities in three European community 
countries (Germany, Portugal , and the Czech Republic). Inclusion criteria 
included: coronary artery disease (CAD) documented either by coronary 
arteriogram or by a coronary event, presence of symptoms of stable angina 
pectoris (SAP) treated by beta-blockers, calcium channel blockers and / or 
sublingual short-acting nitrates ad libitum. Exclusion criteria included: serious 
diseases other than coronary heart disease, hospitalization within one month of 




       






This was an open-label evaluation study performed according to the Safety 
Assessment of Marketed Medicines guidelines.4 After oral informed consent, 
patients were treated for 3 months with 2 to 4 times daily 10-20 mg ISMN/ISDN, 
and, subsequently, for 3 more months with once daily 50 mg ISMN in Portugal and 
the Czech Republic and 120 mg of ISDN in Germany. QOL was assessed after 3 
and 6 month treatment. The primary endpoints were (1) effects on QOL of different 
nitrate dosage regimens and (2) review of the effects of comorbidities. The effects 
on QOL of different nitrate dosages have been reported separately.5 For the effects 
of comorbidities subgroup QOL-domain-scores were analyzed separately from 
Germany and from the other European countries.        
 
QOL-battery 
QOL was measured by a test battery based on the Stewart's6 and Marquis's7 
questionnaires, adapted to current standards8-10, and consisted of five QOL-
domains: mobility-, side-effect-, life-satisfaction-, anginal-pain-, and psychological-
distress-domain (24 items all-in). Items were linearly scored on 5 point scales. 
Mean summary scores were used for evaluation. The study was approved by the 
ethic committees of all of the participating centres. 
 
Statistical analysis 
Paired and unpaired t-tests for quantitative data, and McNemar's and Bowker's 
tests for qualitative data were used. A p-value<0.05 was considered statistically 
significant, standard deviations (SDs) or standard errors (SEMs) were presented. 
Intention to treat analysis was given. For the calculation of the pooled differences 
the correlation coefficients were expected to be at least +0.5 (+0.6 in the DUMQOL 
study).11 The statistical analysis was performed independently of the sponsor by X-






       






Enrolled were 1045 patients, 1010 completed the study, 12 were lost for follow-up, 
23 required more intensive therapy. Mean age was 66.4 (SD 10.2) years, 64.4% 
were males, 64.0% suffered from hypertension, 54.6% from hypercholesterolemia, 
25.7% from diabetes, and 30.6% were smokers, 57.4% were in New York Heart 
Association anginal class II, 25.6%, in class III, 15.5% in class I. No statistically 
significant differences in characteristics were observed between Germany and the 
other European countries. Mean summary domain- scores varied from 4.4 to 16.1 
points, domain-score improvements varied from 1.6 to 4.3 points.  
 
TABLE 1.   Differences in domain-score improvements between anginal patients with and 
without comorbidities (subtractions), indicating better score improvements without 
comorbidities.       
                                                                                                                                                                                
Germany Europe Germany Europe 
Hypertension Smoking 
       
     Differences in domain-score improvements (means (SEMs)) 
 
Mobility-domain -1.0(0.4)** -0.6(0.3)** -0.1(0.4) 0.4(0.5) 
Side-effect-domain -0.3(0.4) -0.1(0.3) -0.2(0.3) 0.1(0.4) 
Life-satisfaction-
domain -0.3(0.2)
* -0.2(0.1)* -0.1(0.3) 0.0(0.2) 
Anginal-pain-domain -0.6(0.3)** -0.3(0.1)* -0.5(0.4) -0.1(0.3) 
Psychological-distress- 
domaine -0.6(0.3)
** -0.5(0.2)*** 0.0(0.4) 0.1(0.3) 
     
Pooled -0.6(0.1)*** -0.3(0.1)*** -0.2(0.1)** 0.1(0.1) 
 
 
* 0.05<p<0.10,  **p<0.05, ***p<0.01 
 
Table 1 shows the effects of comorbidities. Differences in domain-score 
improvements between patients with and without comorbidities are shown 
(subtractions). In Germany mobility-domain improved significantly less in the 
patients with hypertension than it did in the patients without. A difference of -1.0 
 
 
       





points is substantial considering the range of observed score improvements 
between 1.6 and 4.3 points. Also life-satisfaction-domain improved significantly 
less, as did anginal-pain- and psychological-distress-domain. The pooled 
difference was significant at p<0.001. The other European countries gave similar 
results but less substantial. Also in the smokers from Germany, domains improved 
generally less than it did in non-smokers, although not significantly. However, the 
pooled difference was significant at p<0.05. This was not true for the smokers from 
the other European countries, but no deterioration was observed either. In the 
subgroups with diabetes or hypercholesterolemia a reversed pattern was observed 
(Table 2). 
 
TABLE 2.   Differences in domain-score improvements between anginal patients with and 
without comorbidities (subtractions), indicating better score improvements with comorbidities.               
                                                                                                                                                                          
Germany Europe Germany Europe 
Diabetes mellitus Hypercholesterolemia 
                
          Differences in domain-score improvements (means (SEMs)) 
 
Mobility-domain 0.3(0.4)            0.0(0.3)          0.2(0.5)            0.3(0.4) 
Side-effect-domain 0.4(0.4)            0.1(0.2)          0.3(0.4)          0.2(0.2) 
Life-satisfaction-
domain 0.1(0.2)            0.1(0.1)          0.1(0.2)            0.1(0.1) 
Anginal-pain-domain 0.0(0.3)            0.2(0.2)          0.1(0.4)          0.2(0.2) 
Psychological-distress- 
domaine 0.0(0.3)            0.1(0.2)          -0.1(0.3)        -0.2(0.2) 
     
Pooled 0.2(0.1)**           0.1(0.1)          0.2(0.1)* 0.1(0.1) 
  
 
* 0.05<p<0.10,  **p<0.05 
 
In Germany domains generally improved better in the patients with diabetes with a 
pooled difference statistically significant at p<0.05. Also a trend to better 
improvement (0.05<p<0.10) was observed in the hypercholesterolemic patients 
 
 
       





from Germany. The other countries showed no significant improvements, but, 
again, no significant deterioration was observed either.   
 
Discussion 
Patients with CAD and comorbidities like diabetes, hypercholesterolemia, or 
hypertension may less benefit from symptomatic treatment with nitrates, because 
their heart condition may be more severe.1 In contrast, a retrospective study from 
our group showed that this was not true for anginal patient with diabetes or 
hypercholesterolemia.2 Retrospective data are at risk of confounding and have to 
be prospectively assessed. The current study used the same protocol and drug 
regimens, but is otherwise entirely new and prospective in nature. In spite of this, 
the results are remarkably similar: patients with hypertension and smokers 
benefited less from nitrates, while those with diabetes or hypercholesterolemia 
benefited or tended to benefit better. The differences in domain-score 
improvements were more substantial in the patients from Germany, than they were 
in the patients from the other European countries. This is probably due to higher 
dosages of nitrates used. The results of this study confirm that a real effect is 
involved. There are two possible explanations. First, hypertensives and smokers 
may, indeed, represent a category with more advanced CAD, and may, 
consequently, benefit less from nitrates. However, there are no data to support that 
CAD is less advanced in patients with diabetes or hypercholesteremia. Second, the 
difference in nitrate efficacy between comorbidities may be related to differences in 
endothelial dysfunction. Patients with diabetes or hypercholesterolemia are at risk 
of endothelial dysfunction.12-14 Such patients lack endogenous NO-release, and 
may, therefore, particularly benefit from nitrates, being NO-donors. Endothelial 
dysfunction is difficult to assess and systematic studies are lacking. For that 




       






1. Anginal patients with diabetes or hypercholesterolemia derived more benefit  
    from an once-daily regimen of isosorbide mono/dinitrate than did patients 
    without. 
2. Anginal patients with hypertension or smokers did less so. 
3. Differences in endothelial function may be involved.  
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Background: Once-daily nitrate dosages provided better therapeutic efficacy in 
patients with stable angina pectoris, than did multiple daily dosages. Anginal 
patients with cardiovascular comorbidities may particularly benefit from nitric-oxide- 
(NO) donor therapy due to the underlying impairment of endothelium-dependent 
NO-activity.  
Objectives:  
1. To compare QOL and exercise capacity before and after replacement of multiple 
daily with once-daily nitrate therapy.  
2. To investigate the influence of cardiovascular comorbidities on the observed 
changes.  
Methods: Out-patients with stable angina pectoris and at least three months pre-
treatment with 3 times daily 20-40 mg of isosorbide mono-or dinitrate were 
switched to the equivalent single daily dose of the compound early in the morning. 
We assessed predefined QOL-indices, painfree walking distances, New York Heart 
Association (NYHA) anginal class, and the influence of cardiovascular risk factors 
and comorbidities. Standard multi- and univariate methods were applied. 
Results: Of 2675 patients included, 2574 (96.2%) completed the study. After three 
months once-daily nitrate mean QOL-scores improved from 10 to 19% (p<0.0001 
for all of the QOL-domains). The percentage of patients in NYHA anginal class I 
increased by 23.4% (p<0.0001), while exercise capacity increased from a median 
painfree walking distance of 300 to 500 m (p<0.001). In patients with concomitant 
hypertension or hypercholesterolemia anginal class improved better (27.4 and 24.6 
%, both p<0.001). Young age, advanced NYHA anginal class, 
hypercholesterolemia and coronary artery disease (CAD) in the family were 
important independent determinants of the improved QOL.  
Conclusions: Replacement of multiple-dose with once-daily nitrate treatment 
resulted in an improved QOL, anginal NYHA class, and exercise capacity. Patients 
with concomitant hypertension or hypercholesterolemia particularly benefited from 




       






Chronic nitrate treatment is safe and efficacious for the symptomatic treatment of 
stable angina pectoris. Asymmetric dosages regimens provided better therapeutic 
efficacy than did multiple daily dosages 1. Possible explanations include (1) less 
risk of nitrate tolerance with nitrate low periods for several hours per day, (2) better 
patient compliance with once daily dosages, and (3) better protection from the 
circadian peak frequencies of angina pectoris during daytime.  
Nitrates release nitric oxide (NO) from the nitrate molecule. NO has a 
vasoprotective potential, because it has vasodilatory, anticoagulant, and 
antioxidative properties, antagonizes leukocyte-adhesion, and smooth-muscle-
proliferation. These effects are assumed to be clinically relevant, substantiated by 
the fact that a variety of cardiovascular conditions such as hypertension, diabetes, 
hypercholesterolemia, and cigarette smoking are associated with an impairment of 
endothelium-dependent NO activity 2. This could mean that anginal patients with 
such comorbidities might better benefit from nitrate therapy than their counterparts 
without.  
The international survey IQOLAN (International Quality Of Life assessment of 
patients with Angina pectoris on Nitrate therapy) was designed as a multinational 
study, evaluating the effect of a switch from multiple daily to a once-daily nitrate 
treatment on the QOL and anginal symptoms of patients with stable angina 
pectoris. The first objective was to compare predefined quality of life indices and 
New York Heart Association (NYHA) anginal class before versus after replacement 
of multiple daily with once-daily nitrate therapy, and to assess whether the results 
of previous research 3,4 were reproducible in a larger study and across countries. 
The second objective was to investigate the influence of cardiovascular risk factors 




       





Patients and methods 
Design 
Patients were enrolled in Germany, Portugal and the Czech Republic, Latvia, 
Russia, and China. They were switched from multiple daily nitrate (3 times daily 20-
40 mg of isosorbide mono-or dinitrate) to the equivalent single daily dose of the 
compound administered early in the morning (isosorbide dinitrate 120mg in 
Germany, isosorbide mononitrate 50mg in the other countries). A QOL 
questionnaire was completed by each patient before and after the change in 
therapy. In addition, patient satisfaction with the current disease state and 
treatment preference were noted. The physicians assessed exercise capacity, and 
documented the NYHA anginal class as well as information on nitrate therapy 
before and after three months of once-daily nitrate therapy.  
 
Patients 
Outpatients with stable angina pectoris on the above multiple daily dosage nitrate 
therapy for at least three months prior to enrolment were eligible for the survey. An 
adequate knowledge of the local language was required. Patients presenting with 
unstable angina pectoris or myocardial infarction within the last month before 
enrolment, concomitant severe diseases with a possible impact on quality of life, or 
hospitalization within the last month before enrolment were not eligible.   
 
Methods of evaluation 
Prior to and after 3 month once-daily nitrate treatment all of the patients completed 
a validated 5 and previously successfully applied 3,4 24-item English QOL 
questionnaire translated in local language. The items of the questionnaire were 
based on the Short-Form 36 questionnaire of Stewart et al. 6 , the exercise 
tolerance index of Wiklund et al. 7, the pain index of Marquis et al for patients with 
angina 8, the psychological well being index of Dupuy 9, and the distress scale of 
Testa and Simonson 10. From the single items the following domains were defined: 
functional dependence (8 items), anginal pain (5 items), side effects (7 items), and 
psychological distress (4 items). For each item the individual response was scored 
 
 
       





on a 5-point scale from 0 to 4. The sum of score values of each domain was used 
for further evaluation. Higher scores indicated worse quality of life. In addition, data 
on satisfaction with current disease state, the presence of swallowing problems, 
and preference for either the multiple daily or once-daily treatment were collected.  
Patients were also assessed for exercise capacity indicated by the distance a man 
could walk on the flat at a normal pace without anginal pain 11 , and the duration of 
anginal attacks. The physicians reported the individual patient characteristics 
including demographics, eligibility criteria, presence of cardiovascular risk factors, 
cardiac history, the initial nitrate therapy for angina pectoris, as well as concomitant 
therapies. Angina pectoris was classified according to the NYHA class before and 
after 3 month once-daily nitrate treatment. In case the patient did not continue the 
study, the reasons for withdrawal were documented. Information on adverse events 
was collected.  
 
Statistical analysis  
The statistical analysis was performed independently of the sponsor by Xact Vieth 
and Partners, Cologne Germany, using SAS (Statistical Analysis System) version 
6.12. Intention to treat analysis is given. Although all of the indices used in the QOL 
assessment have been demonstrated to have acceptable within-subject test retest 
variability in untreated patients5 , we considered it matter of course to assess 
internal consistency of the multi-item scales and used for that purpose the ratios of 
within- and between-item variances (Cronbach's alphas) 12. Single data entry was 
performed. Data were submitted to several checks of plausibility before the start of 
the evaluation. Data entry errors were corrected. Before the start of the survey it 
was agreed that no queries were generated, not even in the case of inconsistency 
or incompleteness. 
Variables observed before onset of the once-daily nitrate regimen and three 
months later were cross-classified. Qualitative variables were described by 
absolute and relative frequencies (percentages), and tested by the symmetry test 
of Bowker or the test of McNemar, whenever appropriate. Quantitative and the 
scored qualitative variables, as well as the differences between before and after 
 
 
       






change-over were described as means, standard deviations / errors, 95% CIs 
(confidence intervals), medians, lower and upper quartiles, minimums and 
maximums, and tested by the paired t-test. The accumulated data were analyzed 
with and without country-factor as a separate variable. For the latter analysis 
ANCOVA (analysis of covariance) was used. Subgroups were analyzed in an 
exploratory manner using backward multiple regression analysis, and for the 
variable NYHA anginal class by Mantel-Haenszl test, stratified by country. Only 
cases without missing items of the corresponding domain were taken into 






       






In total, 2675 patients were enrolled, with 784 patients (29.3%) in Russia, 606 
(22.7%) in Germany, 605 (22.6%) in China, 379 (14.2%) in Portugal, 241 (9.0%) in 
Latvia, and 60 (2.2%) in the Czech Republic. Of these, 96.2% of all patients 
(n=2574) completed the study (preliminary data from Germany, Portugal, and the 
Czech Republic have been reported 14 ). Of the withdrawals, 30% were lost for 
follow-up, 68% needed more intensive therapy. Coronary artery disease was 
confirmed by angiography and/or previous myocardial infarction in 69.6% of all 
patients. The patient characteristics are shown in Table 1.   
 
TABLE 1.   Patient characteristics. 
 
 n= 2675 
Mean age (years, range) 63.6 (39-99) 
Males (%) 62.1 
Mean body mass index  (range) 26.93 (19.47-39.06) 
Previous coronary arteriography and/ 
or previous myocardial infarction(%) 69.6 
NYHA anginal class I  (%) 10.1 
                                II 49.1 
                                III 33.9 
                                IV 3.9 
Hypertension (n, %) 1872 (70.0) 
Hypercholesterolemia (n,%)                         1624 (60.7) 
Smoking (n,%) 950 (35.5) 
Adipositas (BMI>2.5 kg/m2 ,n,%) 928 (34.7) 
Familial coronary disease (n,%) 918 (34.3) 
Diabetes mellitus (n,%) 618 (23.1) 
Peripheral vascular disease (n,%) 419 (15.7) 
 
 
NYHA= New York Heart Association, BMI = body mass index                                         
 
 
       






FIGURE 1.   Improvement in NYHA anginal class based on n=2675 patients, no data available for 






FIGURE 2 .   Patient compliance as estimated by the answer to the question: did you ever forget 




















       





The number of patients in NYHA anginal class I increased by 23.4% (p<0.0001, 
Figure 1).  
Other benefits included an improved self-reported patient compliance (Figure 2, 
p<0.0001), fewer swallowing problems (p<0.001), less need for additional short-
acting sublingual nitroglycerin ("often" 22.1 and 4.4% of the patients, "never" 8.7 
and 20.2%, multiple and once-daily, respectively, p<0.001), and preference for 
once-daily nitrate in 75.3% of the patients (Figure 3, p<0.0001). The painfree 
walking distance increased from a median of 300 meter (25% quartile: 150 meter, 
75% quartile: 800 meter) to 500 meters (250 and 1000 meter, respectively, 
p<0.001). The duration of anginal pain decreased from a median of 5.0 minutes 
(25% quartile: 2.5 minutes, 75% quartile: 8.0 minutes) to 3.0 minutes (2.0 and 5.0 
minutes, respectively, p<0.001).  
 
FIGURE 3.   Preference for future therapy as expressed by the patients at the completion of the 











       






Figure 4 gives the main results of the QOL-assessments. Cronbach’s alphas were 
>0.7 for all of the QOL-domains indicating that internal consistency of the multi-
item scales were acceptable. So was test-retest reliability with duplicate standard 
errors of the QOL-domains from 1.6 to 2.9%. When the analysis of these QOL-data 
was performed including the country factor as a separate variable, the results were 
virtually the same indicating no major effect of nationality on the variability of these 
data (analysis not shown).    
 
FIGURE 4.   Quality of life scores after 3 month multiple daily and after 3 month once daily 










       





The subgroup analyses are shown in Tables II and III. In patients with concomitant 
hypertension or hypercholesterolemia NYHA anginal class improved significantly 
better than it did in their counterparts without (Table II, p<0.001). In contrast, in 
patients with adipositas or CAD in the family it did significantly less so (p<0.001). 
The multiple regression analysis with QOL improvement as dependent and various 
patient characteristics as independent variables showed that age and NYHA 
anginal class were strong independent determinants of QOL score improvements 
(Table III). In all of the QOL-domains the younger the patients, and the more 
advanced the NYHA anginal class prior to switch, the better the QOL-benefit from 
the once-daily nitrate treatment was observed. Also hypercholesterolemia, and 
CAD in the family was associated with a better QOL-benefit in most of the QOL-
domains, and a trend to better benefit in the accumulated QOL-scores (p<0.07, 
both). The remainder of the subgroup variables including hypertension, diabetes, 
smoking were not strongly associated with better benefit from once-daily nitrate.  
 
TABLE 2.   Subgroup analysis: improvement of NYHA anginal class after 3 month once daily 






95% CI p-value 
Accumulated data                             23.4              21.2-25.6      <0.0001 vs zero 
Patients with diabetes                        23.6              21.6-25.5           ns  vs non-diabetics 
 "        "   smoking                          22.9              20.7-25.0           ns  vs no-smokers 
 "        "   Hypercholesterolemia      24.6              21.6-27.4      <0.001    vs noncholesterolemics 
 "        "    CAD in family                  22.0             19.9-24.0       <0.001    vs patients without 
 "        "    hypertension                 27.4             24.0-30.7       <0.001    vs patients without    
 "        "    PVD                                 24.4             22.5-26.3           ns vs patients without 
 "        "    adipositas                       22.4             20.3-24.5       <0.001    vs patients without 
Males                 24.5             22.2-26.7      ns vs females 
Elderly (>70 years)                               24.6             21.0-28.3           ns    vs patients <70 years 
 
NYHA=New York Heart Association, CI=confidence intervals, vs= versus, CAD=coronary artery 




       




TABLE 3.   Subgroup analysis: independent determinants of QOL-score improvements (backward multiple regression analysis). 
 
 1. physical domain 2. pain domain 





5. life  
satisfaction 6. add-up score 











Age -0.04 0.0004 -0.03 <0.0001 -0.03 <0.002 -0.03 <0.0001 -0.03 <0.0001 -0.13 <0.0001 
 0.01  0.01  0.01  0.01  0.01  0.03  
Gender  ns  ns 0.41 0.05  ns 0.19 0.03  ns 
     0.22    0.09    
NYHA 1.85 <0.0001 1.67 <0.0001 0.63 <0.0001 0.52 <0.0001 0.43 <0.0001 5.72 <0.0001 
 0.18  0.11  0.15  0.10  0.06  0.53  
Diabetes  ns  ns  ns  ns  ns  ns 
Smoking  ns  ns  ns  ns  ns  ns 
Cholesterol  ns  ns 0.05 0.03 0.33 0.03  ns 1.43 <0.07 
     0.02  0.15    0.79  
CAD in family  ns  ns 0.06 0.09 0.30 <0.05 0.33 <0.0001 1.43 <0.07 
     0.02  0.15  0.09  0.79  
Hypertension  ns  ns  ns  ns -0.22 0.02  ns 
         0.01    
PVD  ns  ns 0.58 0.05  ns  ns  ns 
     0.29        
Adipositas  ns  ns  ns  ns  ns  ns 
Concomit.BBs 0.52 <0.04  ns  ns 0.26 0.07  ns  ns 
 0.25      0.15      
Concomit.CCB  ns  ns 0.57 <0.02 0.30 0.06  ns  ns 
     0.24  0.16      
 
 
QOL= quality of life, b = regression coefficient, se = standard error, ns= not statistically significant, NYHA= New York Heart Association, CAD=coronary 






Nitrates are commonly used for the treatment of stable angina pectoris. However, 
so far, little is known about their net effects on QOL. In the current study 3-month-
replacement of multiple daily dose nitrate with a once-daily dosage regimen not 
only improved clinical symptoms but also QOL in all of the domains and in every 
single item. The study was not placebo-controlled, because symptomatic patients 
would have to be withdrawn from active and, generally, recognized treatment, and 
because a double-dummy was not feasible due to the varied dosages. Yet the data 
are in agreement with previous studies 1,2,3 , and the improvements of the exercise 
parameters support the validity of the QOL-assessment. The improvements can be 
explained by less risk of nitrate tolerance. However, better patient compliance has 
to be accounted: higher average plasma levels of NO due to a better patient 
compliance could also explain the improvements observed. Zwinderman et al. 4 
observed similar improvements in 453 patients with stable angina pectoris after 
replacement of 50 mg of isosorbide mononitrate once-daily with 100mg of the 
same compound. Plasma concentrations were not determined in the current study.  
The subgroup analyses showed that QOL improved better in two subgroups: (1) 
the younger, and therefore presumably, more energetic patients, and (2) those with 
advanced NYHA anginal class, and therefore presumably, more symptomatic 
patients. The main purpose of the subgroup analysis was to assess whether 
patients with cardiovascular comorbidities would particularly benefit from NO-donor 
therapy due to the underlying impairment of endothelium-dependent NO- activity. 
In a post-hoc analysis of the DUMQOL data 14, indeed, a slightly better benefit was 
observed in patients with hypercholesterolemia and those with diabetes than in 
their counterparts without. Also, in the current study patients with 
hypercholesterolemia displayed better improvement of anginal class and of most of 
the QOL indices. Better QOL indices and anginal class improvements were also 
observed in patients with CAD in the family and hypertension respectively. 
However, no consistent pattern was observed, and, in particular, the presence of 
diabetes did not influence either anginal class or QOL indices. Of course, the linear 
 
 
       






model assumed in our multivariate assessment may not have been sensitive to 
detect some independent determinants.  
The duplicate standard errors of the QOL-domains from 1.6 to 2.9% suggested an 
acceptable test-retest reliability. A general problem with QOL assessments is its 
lack of sensitivity with heterogeneous populations. Even, small differences like 
language differences are often a major obstacle for such purpose 15. The current 
study shows that it is not impossible to estimate QOL by statistical methods even in 
extremely heterogeneous populations. We should admit that a statistically powerful 
treatment comparison was provided by the self-controlled design which largely 
removed between-subject variability from the treatment comparison, as it was 
based on within-subject comparisons.  
In summary, the results of the IQOLAN survey show, that a switch from a multiple 
daily to a once-daily nitrate treatment regimen resulted in an improvement of QOL 
and anginal NYHA class in patients with stable angina pectoris. These 
improvements were mirrored by an increased patient compliance, increases in the 
painfree walking distance, and a reduced use of additional sublingual nitroglycerin. 
The results support the use of once-daily treatment regimens for long-term nitrate 
therapy for maximized patient compliance and therapeutic benefit. Patients with 
concomitant hypertension, hypercholesterolemia or with CAD in the family 
particularly benefited from an asymmetric dosage regimen, suggesting that an 
underlying impairment of endothelium-dependent NO activity may be involved in 
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CHAPTER 7 




psychosocial determinants to be 
considered by cardiologists 
 














Background: Independent determinants of QOL (quality of life) with heart disease 
have been recognized and include factors like severity of medical condition, 
comorbidity, and concomitant medication. Psychosocial factors, like “ability to cope 
with the unpleasantness of the medical condition”, “want of information”, and 
“social identification” have important influence on self-perceived well-being, but 
their influence on health-related QOL domains and self-perceived QOL in patients 
with heart failure have not been systematically studied.  
Objective: to assess correlation between such psychosocial factors and QOL in 
patients with heart failure. 
Methods: Patients from the outpatient heart failure clinic of the Martini Hospital , a 
1000-bed community hospital in the city of Groningen, Netherlands, were included 
if their ejection fractions were <40% and their medical diagnosis according to their 
cardiologists was stable chronic congestive heart failure. The following QOL-
estimators were applied: Pearlin’s Mastery Scale, Stewart’s Short Form 36 Quality 
of Life Questionnaire, Dupuy’s Index of Well-being, Cantrill’s Self-perceived Quality 
of Life Scale, Mester’s Want of Information Scale. Internal consistency of the multi-
item scales were estimated by Cronbach’s alphas. Linear and multiple linear 
regression analyses were performed of the data.  
Results: Sixty patients were enrolled, 41 males and 19 females, average age 68 
years (range 51-84 years). “Ability to cope with the unpleasantness of the medical 
condition” was not only an independent determinant of self-perceived and health-
related QOL(both p<0.001), but also of each domain of health related QOL 
separately (p<0.001 for each domain). Lack of “adequate medical information” and 
“negative social identification” (the identification with counterparts who are doing 
worse) were negative predictors of “ability to cope” (p<0.01 and <0.001 resp). 
“Negative social identification” also was an independent determinant of self-
perceived QOL, both unadjusted and after adjustment for “ability to cope” and 
“adequate medical information”.      
 
 
       





Conclusions: Relevant recommendations from this paper to be considered by 
cardiologists during everyday office-hours could include:  
1. Patients who express having difficulties to cope with the unpleasant aspects of 
their underlying heart condition, have low health-related QOL as well as low self-
perceived QOL.  
2. Adequate medical information given is a significant contributor to both better 
“ability to cope” and better self-perceived QOL.  
3. Avoiding to identify oneself with counterparts who are doing worse, and, instead, 
starting to identify oneself with counterparts who are doing better, are significant 





       






Patients able to cope with all of the unpleasant aspects of their medical condition, 
generally, have better levels of well-being than those unable to cope 1,2,3. Also the 
correlation between levels of well-being and QOL (quality of life) has been 
demonstrated to be strongly positive 4,5. What are determinants of “ability to cope”? 
It has been suggested that adequate objective information of patients on their 
physicomedical condition is an important factor 3,6. Also, social identification of 
patients with their counterparts has been suggested as a possible contributory 
factor 7,8,9. This may be particularly true for patients from moderate or low social 
class, as not infrequently observed in patients with heart failure 10. We 
hypothesized that in patients with heart failure “inability to cope” would be 
associated not only with low QOL, but also with lack of adequate medical 
information and lack of social identification with the patients’ counterparts. We also 
assumed that the latter factors may be direct contributors to low QOL. In order to 
assess these hypotheses we studied 60 patients with stable chronic heart failure. 
All of the patients were assessed by a test battery consisting of validated 




Patients from the Outpatient Heart Failure Clinic of the Martini Hospital , a 1000-
bed community hospital in the city of Groningen, Netherlands, were included if their 
ejection fractions were <40% and their medical diagnosis according to their 
cardiologists was stable chronic congestive heart failure. Patients were assessed 
by the following battery of validated questionnaires. The Mastery Scale of Pearlin 
and Schooler 11 was used to estimate ability to cope with the unpleasantness of the 
medical condition. The scale consisted of 7 items scored on five point ordinal Likert 
scales ranging from “completely untrue” to “completely true”. Scores were added 
up and divided by numbers of items in order to indicate “ability to cope”. Health-
related QOL was assessed by a validated test battery based on the Short Form 36 
Quality of Life Questionnaire of Stewart 12 and the Index of Psychological Well-
 
 
       





being of Dupuy 13. The adapted form as used by Niemeijer 14 and Zwinderman 15 
consisted of 19 items also scored on 5 points: 8 items addressing the physical 
domain, 7 items the pain domain, and 4 items the psychological domain of QOL. 
As the above QOL battery was developed for patients with coronary heart disease 
in general, 3 items were added to address specific symptoms of heart failure, 
including shortness of breath at rest, shortness of breath with exercise, and (ankle) 
oedema. Also 3 items were added to address social problems rising from the 
medical condition. Again scores were added up and divided by numbers of items to 
estimate overall scores in different QOL domains.  
Self-perceived QOL was assessed by Cantrill’s Stair Diagram 16.It was scored on a 
10 point scale: number 0 for the worst , number 10 for the best self-perceived QOL.  
Lack of adequate medical information was assessed by Mester’s Want of 
Information Scale 17. Six items were scored on 5 point scales. 
Social identification, either positive (identification with counterparts who are doing 
better) or negative (identification with counterparts who are doing worse) were 
assessed by two scales of 8 items each and again scored on 5 point scales. The 
scales were developed by one of the authors who is a recognized expert in the 
field of social comparisons 7,8,9. 
Internal consistency of the multi-item scales were estimated by Cronbach’s alphas. 
This coefficient represents the proportion of variance due to the true scores as 
compared to the overall variance in the data including measurement error. It has a 
maximal value of 1.0 whereas a value above 0.7 is recommended to ensure 
acceptable reliability.  
All of the patients answered their questionnaires without assistance of the 
physician. Linear and multiple linear regression analyses of the accumulated data 
were performed. Under the assumption of pooled scores of at least 50% and 
differences between pooled scores of at least 10%, and clinically relevant within-
group correlations of at least +0.6, the study would have to include 61 patients to 
obtain a statistical power of 80% and a 5% significance level. The study was 




       











Sixty patients were enrolled, 41 males and 19 females. Average age 68 years 
(range 51-84 years).  
Table 1 gives an overview of levels of internal consistency of the various 
questionnaires, which were adequate without exception. “Ability to cope with the 
unpleasantness of the medical condition” was not only an independent determinant 
of self-perceived and health-related QOL but also of each domain of health-related 
QOL separately (p<0.001 for each domain, Table 2).  
 
TABLE 2.   Linear regression analysis of the determinant “ability to cope with the unpleasant-
ness of the heart condition” on health-related QOL and self-perceived QOL. 
 
 R square    Regression coefficient    P-value         
Self-perceived QOL                      0.46                 1.62                    <0.001 
Health-related QOL:                        
    Overall                                       0.44               0.65                  <0.001 
    Physical domain                         0.20                 1.0                     <0.001 
    Pain domain                               0.21                 0.29                 <0.001 
    Psychological domain                0.29                 0.54                   <0.001 
    Symptoms of heart failure          0.23                  0.55                  <0.001 
    Social domain                            0.44                  0.55                  <0.001 
 
 Number of items     Cronbach’s alpha         
The Mastery Scale of Pearlin and Schooler   7   0.73   
Health-related QOL Questionnaire:         
                   Physical domain                                       8 0.91 
                   Pain domain                                             7 0.75 
                   Psychological domain                                4 0.74 
                   Symptoms of heart failure                         3 0.69 
                   Social domain                                            3 0.91 
Mester’s Want of Information Scale                         6 0.87 
Positive social identification                                           8 0.91 




       





Table 3 shows that lack of “adequate medical information” and “negative social 
identification” (the identification with counterparts who are doing worse) were 
strong negative predictors of “ability to cope” (p<0.01 and <0.001 resp). Table 4 
shows that “negative social identification” also was an independent determinant of 
self-perceived QOL. This was so both unadjusted and after adjustment for “ability 
to cope” and “adequate medical information”.  
 
TABLE 3.  Linear regression analysis of the determinants “adequate medical information”, 
“positive social identification”, and “negative social identification” on “ability to cope with the 
unpleasantness of the heart condition”. 
 
 R square    Regression coefficient   P-value         
“Adequate medical information”    0.15                  -0.36                         <0.01        
“Positive social identification”       0.04                  0.28                           ns 
“Negative social identification”      0.20                  -0.59                        <0.001   
 
 
TABLE 4.    Linear regression analysis of the determinants (1) “positive social identification” and 
(2) “negative social identification” on self-perceived QOL. 
 
 R square    Regression coefficient P-value         
“Positive social identification”         0.04                  0.36                           ns 
“Negative social identification” *     0.34                -0.58                        <0.001 
 
* The “negative social identification” remained a statistically significant determinant of self-perceived 
QOL (p<0.01) after adjustment for “ability to cope” and “adequate medical information”.    
 
Discussion 
As expected, “ability to cope with the medical condition” largely determined QOL. 
No less than 46% of the variance in the self-perceived QOL was determined by the 
variance in the “ability to cope” (Table 2). Adequate medical information improved 
both “ability to cope” and self-perceived QOL. While a “positive social identification” 
(social identification with counterparts who are doing better) did not change self-
perceived QOL or “ability to cope”, a “negative social identification” (social 
identification with counterparts who are doing worse) deteriorated both factors, 
 
 
       






either tested separately or simultaneously. It is remarkable that the negative 
influence of “negative social identification” was a lot stronger than the positive 
influence of “positive social identification”. Possible explanations for this 
unexpected discrepancy include: (1) negative events and experiences, generally, 
have a more profound impact on personal life than positive ones 18 ; (2) patients 
with heart failure are, particularly, at risk of being depressed and, maybe therefore, 
less able to identify themselves with those who are doing better 19.  
A limitation of the present study is that it did not test all of the correlations 
simultaneously. For such purpose LISREL’s method 20 should be used. However, 
our sample size did not provide enough power to apply this method reliably. 
Nonetheless, our results are impressive and largely confirm our prior hypotheses. 
They will be used by our group for the development of an intervention program to 
improve QOL with heart failure, currently in progress at our departments. In the 
meantime, relevant recommendations to be considered by cardiologists for their 
everyday office-hours could include:  
Patients who express having difficulties to cope with the unpleasant aspects of 
their underlying heart condition, have low health-related QOL as well as self-
perceived QOL.  
Adequate medical information given is a significant contributor to both better “ability 
to cope” and better self-perceived QOL.  
Avoiding to identify oneself with counterparts who are doing worse, and, instead, 
starting to identify oneself with counterparts who are doing better, are significant 






       






1. Cohen F. Coping with surgery: Information, psychological preparation, and 
recovery. In: L.W.Poon (Ed.). Aging in the 1980’s: Psychological issues (pp. 
375-382). Washington, D.C.: American Psychological Association, 1980. 
2. Cohen S, Edwards JR. Personality characteristics as moderators of the 
relationship between stress and disorder. In: R.W. Neufeld (Ed.). Advances 
in the investigation of psychological stress (pp. 235-283). New York: John 
Wiley & Sons, 1989. 
3. Cohen F, Lazarus RS. Coping with the stress of illness. In: G. Stone, F. 
Cohen, & N. Adler (Eds.). Health Psychology. San Fransisco: Jossey-Bass, 
1979. 
4. Abbey A, Andrews FM. Modelling the psychological determinants of life 
quality. Social Indicators Research. 1985; 16: 1-34. 
5. Taylor SE, Brown JD (1988). Illusion and well-being: A social psychological 
perspective on mental health. Psychological Bulletin. 1988; 103: 193-210. 
6. Felton BJ, Revenson TA (1984). Coping with chronic illness: A study of 
illness controllability and the influence of coping strategies on psychological 
adjustment. Journal of Consulting and Clinical Psychology. 1984; 52: 343-53. 
7. Buunk BP, Collins RL, Taylor SE, VanYperen NW, Dakof GA (1990). The 
affective consequences of social comparison: Either direction has its ups and 
downs. Journal of Personality and Social Psychology. 1990; 59: 1238-49. 
8. Buunk BP, Ybema JF. Social comparison and occupational stress: The 
identification contrast model. In: B.P. Buunk, & F.X. Gibbons (Eds.). Health, 
coping and well-being: Perspectives from social comparison theory (pp. 359-
388). Mahwah, NY: Lawrence Erlbaum Associates, 1997. 
9. Van der Zee K, Buunk B, Sanderman R, Botke G, Van den Bergh F. Social 
comparison and coping with cancer treatment. Personality and individual 
differences. 2000; 28: 17-34. 
10. Westlake C, Dracup K. Predictors of quality of life for patients with advanced 
heart failure. Circulation. 1998; 97: 482 (Suppl 1). 
 
 
       






11. Bland JM, Altman DG. Statistics notes. Cronbach’s alpha. Br Med J . 1997; 
314: 572-3. Pearlin LI, Schooler C. The structure of coping. Journal of Health 
and Social behavior. 1978; 19: 2-21. 
12. Stewart AH, Hays RD, Ware JE. The MOS short-form general health survey: 
reliability and validity in a patient population. Medical Care. 1995; 26: 724-35. 
13. Dupuy HJ. The psychological well-being index. In: N.K. Wenger, M.E. 
Matson, C.D. Furberg, & J. Elinson (Eds.). Assessment of quality of life in 
clinical trials of cardiovascular therapies (pp. 170-183). Le Jaq Publishing, 
1984. 
14. Niemeijer MG, Kleinjans HAJ, De Ree R, Zwinderman AH, Cleophas TJM, 
Van der Wall EE. Comparison of multi-dose and once-daily nitrate therapy in 
1212 patients with stable angina pectoris: Effects on quality of life indices. 
Angiology. 1997; 48: 855-62. 
15. Zwinderman AH, Cleophas TJ, Niemeijer MG, Van der Wall EE. Effects of 50 
mg and 100 mg isosorbide mononitrate once daily on quality of life in 
patients with stable angina pectoris. Angiology. 1999; 50: 949-65. 
16. Cantril H. The pattern of human concerns. New Brunswick, NJ, Rutgers 
University Press, 1965. 
17. Nederlandse Hartstichting. Brochure: Hartfalen. Mouthaan Grafisch bedrijf, 
Papendrecht, 2000. [Dutch Heart Foundation, (2000). Information Pamflet: 
Heart Failure.]. 
18. Taylor SE, Helgeson VS, Reed GM, Skokan LA. Self-generated feelings of 
control and adjustment to physical illness. Journal of Social Issues. 1991; 47: 
91-109. 
19. Sykes DH, Hanley M, McC Boyle D, Higginson JDS, Wilson C. 
Socioeconomic status, social environment, depression and postdischarge 
adjustment of the cardiac patient. Journal of Psychosomatic Research. 1999; 
46: 83-98. 
20. Jöreskog KG, Sörbom D. LISREL 8: User’s reference guide. Mooresville, IN: 




       





































































J.R. van der Veen, R.M.G. Jansen,  




Quality of life of 
patients on the waiting 
list for coronary 
angiography 
 













Background: Providing adequate medical information and avoiding patients to 
identify themselves with fellow-sufferers were significant contributors to better 
quality of life (QOL) in cardiac patients. Gender and level of psychic tension were 
significant predictors of QOL in cardiac patients. We don’t know (1) whether we can 
improve QOL by increasing patients’ ability to cope with the unpleasant aspects of 
the underlying condition, (2) whether gender and level of psychic tension interact or 
act independently. 
Objective: to assess both questions. 
Methods: 38 patients on the waiting list for coronary angiography were assessed 
with validated test batteries. To increase the patients’ ability to cope, they were 
randomly assigned to read either (1) the comments of a patient previously 
successfully treated or (2) general information about the procedure. The former 
information, unlike the latter, was assumed to improve coping ability and, thus, 
provide better QOL. Homogeneity of the patient group was estimated by 
Cronbach’s alphas. For analysis linear regression and general factorial analyses of 
variance were applied. 
Results: The group was psychologically homogeneous as indicated by Cronbach’s 
alphas being, generally, over 75%. There was a significant or close to significant 
association of presence of coping information with a better mobility, social 
performance and self-perceived QOL (p<0.05, p<0.06, and p = 0.10).High levels of 
psychic tension were associated with low self-perceived QOL and low 
psychological scores (both p<0.02). Female gender was associated with lower 
mobility, lower psychological scores and lower overall QOL (p<0.05, p<0.02 and 
p<0.05). A significant or close to significant interaction was observed between 
gender and psychic tension as combined determinants of self-perceived QOL, 
mobility index, and overall QOL index (p<0.03, p<0.09, and p<0.05). Separate 
assessments of these determinants showed that the female gender was the 
strongest determinant of low QOL. 
 
 
       






1. In patients on the waiting list for coronary angiography, an increased ability to 
cope with the unpleasant aspects of a possible underlying heart condition 
improves QOL. 
2. Female gender and a high level of psychic tension places patients at risk of low 
QOL.  
It is to be hoped that this paper raises the physicians’ awareness of such 
psychological mechanisms, and that, particularly, future female patients will receive 





       







Therapeutic interventions have been demonstrated to beneficially influence quality 
of life of patients with cardiovascular conditions. E.g. once-daily dosage schedules 
of nitrates significantly improved quality of life (QOL) in patients with stable angina 
pectoris.1,2 In the past few years also psychological interventions have been 
successfully employed. Particularly, providing adequate medical information3 and 
avoiding patients to identify themselves with fellow-sufferers who are doing worse, 
and , instead, identifying themselves with those who are doing better, were 
significant contributors to both better ability to cope with the unpleasant aspects of 
the underlying condition and better self-perceived quality of life.4-8 However, we 
don’t know whether we can improve QOL by increasing patients’ ability to cope. 
Gender 9-12 and psychic tension 13,14 have been recently recognized as important 
determinants of QOL. Females, unlike males, underestimated their level of health, 
suffered more than their male counterparts from health problems and chronic 
conditions, used more medicines 9,10 , and felt sicker than men.8 Females with 
cardiovascular disease had lower QOL than had their male counterparts.15 Psychic 
tension influences QOL, probably, because it induces a negative mood which is a 
strong predictor of symptoms and health complaints.13,14 However, we don’t know 
whether these two factors interact or act independently. 
Patients on the waiting list for coronary angiography are, of course, somatically 
heterogeneous, but psychologically they are less so. We assumed that a group of 
patients meeting the Cronbach’s criterium for consistency 16 would qualify for 
assessing the following questions:  
1. Can we improve QOL by increasing the patients’ ability to cope with the 
unpleasant aspects of a possible underlying heart condition? 
2. Are gender and psychic tension independent determinants of QOL in this 
category of patients, and do these two factors interact or act independently? 
To assess these questions we studied 38 patients all of whom were to be assessed 
by test batteries consisting of validated questionnaires. Linear regression and 
general factorial analyses of variance were used.   
 
 
       






In the period between May and August 2004 38 patients gave their informed 
consent. Each patient had been examined at the outpatient Cardiology Clinic of the 
Martini Hospital, a 1000 bed teaching hospital in the city of Groningen, 
Netherlands, and was included if his/her knowledge of the Dutch language was 
adequate. The protocol was approved by the institutional ethic committee. 
Patients were assessed by the following battery of validated questionnaires. 
Health related QOL was assessed by the DUMQOL (Dutch Mononitrate Quality of 
Life) Questionnaire.1,2 It consisted of 19 items scored on 5 points: seven items 
addressed the physical domain, six the pain domain, four the psychological 
domain, and three the social domain. Self- perceived QOL was assessed by 
Cantril’s Stair Diagram.17 It was scored on a ten-point scale: number 0 for worst, 
number 10 for the best self-perceived QOL.   
Social identification with fellow sufferers who are doing worse or better was 
assessed by the Iowa-Netherlands Comparison Orientation Measure (INCOM).18 
The scale consisted of 11 items scored on 5 points.  
In order to increase the patients’ ability to cope with the unpleasant aspects of a 
possible underlying heart condition, patient were randomly assigned to read either 
(1) the comments of a patient previously successfully treated or (2) general 
information about the procedure. We assumed that the former information, unlike 
the latter, would improve coping ability and, thus, provide better QOL, and defined 
the assigned subgroups as respectively the coping-information-subgroup and the 
neutral-information-subgroup. 
Finally, the presence of psychic tension was assessed by a standard questionnaire 
routinely used for that purpose at our department and consisting of three items 
scored on 7 points (1= no, 7 maximal psychic tension). All of the scores were 
added linearly and divided by the numbers of items in order to obtain overall 
scores. 
    
 
 
       
















This criterium represents the proportion of variance due to the true scores as 
compared to the overall variance in the data including the measurement error. It 
has a maximal value of 1.0 whereas a value above 0.7 indicates an acceptable 
reliability and reproducibility in the data. For analysis we used linear regression 
analyses and general factorial analyses of variance using the groups means as 
main effects and the combined effects of the factors as interactive effects. If a 
significant interaction effect was demonstrated, differences in the subgroups were, 
subsequently, assessed separately by linear regression. We used Excel data files19 
and SPSS Statistical Software.20  
 
TABLE 1.   Cronbach’s criterium of consistency16 of the multi-item DUMQOL  and the other 
questionnaires as calculated from the current study data indicating, generally, a good 
reproducibility. 
 
 Cronbach’s alpha* 
1. DUMQOL questionnaire   Mobility domain                   0.91             
2.                                            Pain domain                         0.82   
3.                                            Psychological domain           0.60 
4.                                            Social domain                        0.75 
5. Social Comparison Orientation Measure                        0.77 
6. Psychic Tension questionnaire                                        0.76 
 
*A value above 0.7 indicates acceptable reliability and reproducibility in the data. 










                                          k = number of items 
                                       s2i  = variance of ith item  
                                       s2T  = variance of total score obtained by summing up  
                                                all of the items 
 
 
       






The study group consisted of 21 males and 17 females, mean age 68 (standard 
deviation 7.9) years, range 46 to 82 years. Of the patients 34 (90%) had a partner, 
14 (37%) were underwent the intervention for the second time. Except for the 
psychological domain of the DUMQOL questionnaire, the internal consistency and 
reliability of the questionnaires was adequate, underscoring both the reproducibility 
of the questionnaires and the homogeneity of the study group (Table 1). 
 
TABLE 2.   Linear regression analyses of the associations between QOL estimators and the 





 R2    p-value 
1. Mobility domain                     0.39                       <0.05 
2. Pain domain                            -   ns 
3. Psychological domain            -     ns 
4. Social domain                         0.26                       <0.06 
 
*The significant association was lost after adjustment for social comparison orientation 
(linear regression); R2 = Pearson’s correlation coefficient squared. 
 
Table 2 assesses the strength of the associations between the QOL estimators and 
the ability to cope as estimated by the presence of coping-information or neutral-
information. There was a significant and close to significant association between 
the presence of coping-information with both a better mobility and a better social 
performance. The presence of coping-information may indeed produce better QOL, 
at least in these two domains of the DUMQOL battery. A similar trend was 
observed with the Cantril’s Self-perceived Quality of Life Scale, although 
significance was not obtained here (p=0.10). The significant associations were lost 
after adjustment for social comparison orientation using factorial analysis of 
variance with the INCOM Questionnaire as second dependent variable. 
Table 3 gives the results of the factorial analyses of variance of the effects of the 
determinants gender and psychic tension on various QOL estimators.  
 
 
       






TABLE 3.   General factorial analyses of variance of the associations of gender, psychic tension 
and their interaction with various QOL estimators.  
 
Gender Psychic tension                                      
Interaction gender x 
psychic tension  
b p-value  b p-value  b p-value 
1. Cantril’s Self- perceived 
    Quality of life Scale           
-0.57   ns   -0.92    <0.02   -1.13      <0.03 
2. Mobility domain                   -0.71   <0.05   0.07      ns      -0.53      <0.09 
3. Pain domain                     -0.15    ns -0.21   ns     -0.19         ns 
4. Psychological domain      -0.45   <0.02    -0.35   <0.02       -0.05         ns 
5. Social domain                   0.05    ns      -0.23     ns       0.01         ns 
6. Overall (2-6)                    -0.46    <0.05   -0.01     ns       -0.04       <0.05 
 
b = regression coefficient 
 
Psychic tension was inversely correlated with Cantril’s Self-perceived QOL Scale; 
the lower the psychic tension the better the QOL. Female gender was correlated 
with the lower scores in the mobility, psychological and overall QOL of the 
DUMQOL battery, while high psychic tension was correlated with lower scores in 
the psychological domain. As indicated in the Table 3, a significant or close to 
significant interaction was observed between gender and psychic tension as 
combined determinants of the Cantril’s QOL scores, mobility DUMQOL and overall 
DUMQOL scores. Because a significant interaction overrules the conclusion of 
independence of the separate determinants, we performed simple linear regression 
analyses of these determinants for either gender. The figures 1-3 show that 
psychic tension is a stronger determinant of QOL estimators in females than it is in 
males. Obviously, in males, unlike females, QOL estimators are little influenced by 




       




































b = -0.92 
p < 0.001 
b = -2.05 
p < 0.001 
 
Discussion 
The study showed a significant (p<0.05) and close to significant (p<0.06) 
association of the presence of coping-information with mobility and social indices of 
QOL, and a similar trend was observed with the Cantril’s self-perceived QOL 
Scale. This suggests that a better ability to cope may indeed improve some QOL 
estimators. However, the magnitude of these effects is less impressive than it was 
in our previous study where an association of coping ability was found at p<0.001 
with all of the QOL estimators.3 There are several explanations for this difference: 
(1) a study with a small sample size can hardly produce low p-values, (2) a 
different evaluation / assessment of coping ability was applied. Also (3) the 
difference could be explained by the presence of more females in the present 
study: 45% compared to 30 % of the patients in the previous study. To date no 
studies showing gender differences in coping ability have been published, but 
gender differences of other psychological factors like psychic tension have been 
established before. Despite the less impressive result, the two studies are in line, 
and support the findings of investigators who studied other medical conditions for 
the effects of coping on QOL.21-24 
 
FIGURE 1.   Mean effects of level of psychic tension on Cantril’s Self-perceived QOL scale;              














       


























b = -0.46 
p < 0.05 
The current study found a significant association of psychic tension, gender as well 
as their combination with various QOL estimators. When females and males were 
assessed separately, psychic tension was a much stronger determinant of QOL 
estimators in females than it was in males. Obviously, in females a high level of 
psychic tension reduces QOL more than it does in males. The present study can 
not only confirm that females at the waiting list for coronary angiography are more 
tense than males, but can also conclude that their QOL is lower, possibly as a 
consequence of being more tense. The price of women’s longer life expectancy 
has to be paid in terms of a life with more psychic tension and less QOL. The 
current paper provides, thus, further support for Nathanson’s legendary statement: 
“women get sick, men die”.11      
 
















Many differences have been recognized to exist between women and men with 
coronary heart disease.25,26 Usually, women will develop a heart attack about 10 
years later than men, probably because they are protected by a higher HDL 




       




























b = -0.40 
p < 0.03 
b = -0.01 
ns 
cholesterol premenopausally, but at the same time suffer from more risk of 
diabetes due to associated obesity, higher frequency of metabolic syndrome, twice 
the risk of heart attack due to smoking. Women may not experience the crushing 
chest pain that is a classic symptom of a heart attack in men, and also have 
smaller coronary arteries, making various intervention more difficult to do. They 
may not talk to their physicians about coronary risks and may not recognize the 
symptoms, mistaking them for signs of panic disorder, psychic tension or 
hypochondria. The current paper demonstrates psychological mechanisms that are 
obviously different between males and females, and may contribute to the above 
differences in behaviour patterns. 
 
















We conclude that: 
1. In patients at the waiting list for coronary angiography, an increased ability 
to cope with the unpleasant aspects of a possible underlying heart 
condition improves QOL. 
 
 
       





2. Female gender and a high level of psychic tension places patients at risk of 
low QOL.  
 
It is to be hoped that this paper raises the physicians’ awareness of such 
psychological mechanisms, and that, particularly, future female patients will receive 




       









A self-administered questionnaire comprising of 21 items of five point scales 
on three important areas of quality of life, based on the Short Form 36 
questionnaire of Stewart27, the exercise tolerance index of Wiklund28, the pain 
index for patients with angina pectoris of Marquis29, the psychological well-
being index of Dupuy30, as well as the distress scale of Testa31. 
 
Cantril’s stair diagram 
A diagram shaped like stairs, with number one at the bottom and number ten 
at the top. People have to place themselves on the stairs according to their 
current well-being. When they place themselves at the bottom it means that 
they rate their well-being as bad. The more they place themselves towards 
the top, the more they feel their well-being is good. 
 
INCOM questionnaire 
The Iowa-Netherlands Comparison Orientation Measure. A validated 
measure of the tendency to make social comparisons. Assuming that the 
tendency toward social comparison is universal, the scale was constructed so 
as to be appropriate to and comparable in 2 cultures: American and Dutch18.  
 
Cronbach’s alpha  
Cronbach's alpha measures how well a set of items (or variables) measures a 
single unidimensional latent construct. When data have a multidimensional 
structure, Cronbach's alpha will usually be low. Technically speaking, 
Cronbach's alpha is not a statistical test - it is a coefficient of reliability (or 
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CHAPTER 9 
Early discharge  
(24-36 hours) after 

















Objective: The objective of this study is to investigate the feasibility of a short-stay 
protocol after myocardial infarction (MI) and primary percutaneous transluminal 
coronary angioplasty (PTCA) in a selected low-risk population and to evaluate 
Quality of life (QOL).  
Methods: patients eligible for the study had acute MI, treated successfully with 
primary PTCA. Inclusion criteria included single vessel disease, TIMI 3 flow after 
the procedure combined with a good myocardial blush and absence of heart 
failure. Patients meeting the inclusion criteria were discharged 24 to 36 hours after 
admission, and visited the outpatient clinic (where they were seen by a specialised 
nurse) on the third and fourth day. Consecutively, they were enrolled in the 
standard rehabilitation program. We evaluated re-infarction, re-admission or visits 
to the emergency department in the follow-up period of three months. Furthermore, 
we evaluated quality-of-life scores and secondary prevention goals at the end of 
the follow-up period. 
Results: 46 patients were included in the study. Mean age was 55 yrs (37-73 yrs), 
26 patients (57%) were current smokers, 4 patients (9%) had diabetes mellitus and 
13 patients (28%) were known with hypertension. There were 12 patients with 
anterior infarction (26%).  Mean CK was 1016 U/L (range 95-4333), CK-MB 118 
U/L (range 13-374). Mean left ventricular ejection fraction 1 week after infarction 
was 59% (range 39%-77%). Patients were discharged after a mean of 29 hours 
(standard deviation 6.6, range 20-48 hours). During the follow-up period, there 
were no re-infarctions or re-admissions. After three months 17 of the 26 patients 
who smoked on admission had not resumed smoking. Mean total cholesterol was 
3.9 (on admission 5.4) and mean blood pressure 127/75 (on admission 138/83). 
On exercise testing, none of the patients showed signs of myocardial ischemia and 
mean performance was 97% of the expected value. QOL scores on 3 scales 
(emotional, physical and social well being), taken both 1 week after discharge and 
after 3 months, were excellent.  
 
 
       





Conclusion: After acute MI and primary PTCA, hospital discharge on the day after 
admission in combination with outpatient visits and a rehabilitation program is 
feasible and offers a safe and patient-friendly alternative to the usual 3 to 4 days of 




       






The last decade’s considerable improvement has occurred in the process of care 
for patients with ST-elevation myocardial infarction (STEMI). Primary percutaneous 
coronary intervention has become the preferred (first choice) therapy for acute 
myocardial infarction with ST elevation in most developed countries. It has 
demonstrated to be more effective than thrombolysis in restoring TIMI 3 flow and 
thus decreasing mortality and morbidity 1,2,3. This also has a consequence on the 
length of stay of patients with ST elevation myocardial infarction. In 1988 A 
randomised trial of early discharge by Topol 4 showed the safety of discharge on 
the third day after infarction in selected patients (thrombolysis and angioplasty 
patients). In recent years there have been suggestions that an even shorter 
hospital stay may be safe for some STEMI patients. However, a difficulty in 
introducing early discharge after myocardial infarction is the identification of 
patients who have uncomplicated disease or are at low risk of death. This 
assessment is needed very early after admission so that the patients can be given 
appropriate treatment and health education in the few time that they spend in 
hospital. Although several scores have been introduced as useful tools for bedside 
risk stratification for patients with STEMI 5,6,7,8,9,10 they can not be fully be applied to 
patients treated successfully with angioplasty. Therefore we recently described an 
easy and practical score for early risk stratification in patients with ST-segment 
elevation treated with primary angioplasty 11. This score reliably identifies a large 
group of patients at very low risk, who may safely be discharged early after primary 
angioplasty. The score is based on coronary anatomy and flow parameters and 
can be applied immediately after the percutaneous coronary intervention. As a 
consequence, we developed a pilot study that evaluates a short-stay protocol after 
myocardial infarction (MI) and primary percutaneous transluminal coronary 
angioplasty (PTCA) in a selected low-risk patient population. This protocol included 
intensive out-patient follow up and cardiac rehabilitation for secondary prevention 




       






We evaluated a short stay protocol after myocardial infarction that included an 
intensive out patient follow up conducted by specially trained cardiac rehabilitation 
nurses at our hospital.  
Patients eligible for the study had acute myocardial infarction treated successfully 
with primary PTCA. Procedural success was assessed by the physician and 
defined as an uncomplicated procedure resulting in TIMI 3 flow with a good 
myocardial blush in the infarct related vessel. In addition, eligible patients had 
single vessel disease and no signs of heart failure (defined as KILIP class I). These 
inclusion criteria reflect a Zwolle risk score of 3 or less 11. This score is a practical 
and useful index for risk stratification after primary angioplasty for STEMI. Total 
score can range from 0 to 16, reflecting respectively a low and high risk for 30 day 
mortality. Patients with a score of 3 or less are at a very low risk for mortality (0.1% 
at 2 days, 0.2% at 3 to 10 days, and 0.5% at 30 days) after treatment with PTCA 
for STEMI. An outline of the Zwolle risk score is given in figure 1. 
After informed consent was obtained, the patient was seen by the research nurse 
of the cardiac rehabilitation department. Patients received discharge instructions 
about recognizing acute cardiac symptoms and appropriate actions to take into 
response to ensure early evaluation and treatment should symptoms occur. 
Depending on the time of admittance, patients were discharged from the hospital 
24 to 36 hours after admittance. The first and the second day after discharge, 
patients were seen by the research nurse of the cardiac rehabilitation department. 
During these out-patient visits, an ECG and laboratory samples were taken. Also a 
physical examination was performed. If necessary, medication was adjusted. 
Standard medication included beta-blocker, aspirin, statins, clopidogrel and if 
appropriate ace inhibition. After 1 week, nuclear ejection fraction measurement was 
performed. Immediately after discharge, the patients were also enrolled in the 
rehabilitation program. This rehabilitation program focused on education and 
actively involves patients in planning for adherence to lifestyle changes and drug 
therapies that are important for the secondary prevention of cardiovascular 
diseases. Patients were also given the possibility of supervised exercise training at 
 
 
       






our hospital. We evaluated re-infarction, re-admission or visits to the emergency 
department in the follow-up period of three months. Furthermore, we evaluated 
quality-of-life scores and secondary prevention goals at the end of the follow-up 
period. For QOL evaluation, we used the Dutch translation of the “Quality of Life 
after Myocardial infarction instrument” (QLMI) 12. This questionnaire consists of 24 
questions to measure health-related quality of life for patients after myocardial 
infarction. QOL is measured on three subdomains, the emotional domain, the 
physical domain, and the social domain. The sum of the score on the various 
domains gives the total quality of life score. The higher the score is, the better the 
QOL. The maximum total score is 168, reflecting the best possible QOL status, the 
minimum score is 20. 
 
FIGURE 1.   Zwolle risk score for STEMI.  
 
 Points 










> or = 60  2 
3 vessel disease  
No 0 
Yes  2 
Anterior Infarction  
No 0 
Yes 1 
Ischemia time (> 4 hours)  
No 0 
Yes 1 
Total score 16 
 
 
       






From July 2004 to September 2005, 46 patients were included in the study. Mean 
age was 55 yrs (37-73 yrs), 26 patients (57%) were current smokers, 4 patients 
(9%) had diabetes mellitus and 13 patients (28%) were known with hypertension. 
There were 12 patients with anterior infarction (26%). Mean CK was 1016 U/L 
(range 95-4333), CK-MB 118 U/L (range 13-374). Mean left ventricular ejection 
fraction (nuclear measurement, using the enigma protocol) was 59% (range 45%-
77%). Patients were discharged after a mean of 29 hours (SD 6.6, range 20-48 
hours). The demographics are also represented in table 1. During the follow-up 
period, there were no re-infarctions or re-admissions. 6 patients visited the 
emergency department within the 3 months after discharge; however, in these 
patients there were no signs of cardiac ischemia and these patients were 
discharged from the emergency department. 
 
TABLE 1.   Demographics.  
 
Total N = 46 % 
Male 36 78 
Female 10 22 
Known CAD 3 7 
Prior infarction 2 4 
DM 4 9 
Hypertension 13 28 
Anterior infarction  12 26 
Stent 43 94 
    
The medication use at discharge and follow up is given in table 2. After three 
months 17 of the 26 patients who smoked on admission had not resumed smoking 
(table 3). Mean total cholesterol was 3.9 (on admission 5.24) and mean blood 
pressure 127/75 (on admission 138/84). On exercise testing, none of the patients 
showed signs of myocardial ischemia and the mean performance was 97% of the 
expected value. QOL scores were evaluated in 25 patients. 1 week after discharge, 
the sum of the QOL score was 146, which reflects the 9th deciles as compared tot 
 
 
       






404 Dutch cardiac patients with different types of cardiac incidents (Myocardial 
infarction, CABG and PTCA). QOL at 3 months was better than baseline for all of 
the three subscales, with a total score of 161, reflecting an excellent QOL state in 
this selected patient population. 
 
TABLE 2.   Medication.  
 
Medication Discharge 3 months 
Aspirine (%) 100%  97.8% 
ACE/I (%) 56.5% 52.2% 
Beta Blocker (%)  100%  80.4% 
Clopidogrel (%)  100% 50% 
Statin (%) 100%  91.3% 
 
 
TABLE 3.   Secundary prevention. 
 
 Admission 3 months 
Smoking (%) 56.5%  19.6% 
Smoking ever (%)  67.4%  
Cholesterol (mean)  5.4 3.9 
Blood Pressure (mean) 138/84 127/75 
 
 
TABLE 4.   Quality of life scores, hihger scores indicate better QOL. 
 
Domain  1 week 3 months 
Physical  42 48 
Social  42 47 
Emotional 62 66 
Total*  146**  161*** 
 
 
* These scores reflect excellent QOL state compared to 404 Dutch cardiac patients with different types 
of cardiac incidents   
 
** 9th percentile 
 
*** 10th percentile 
 
 
       






Despite extensive research there is still a lot of variation between countries in 
length of stay patterns in patients treated for acute myocardial infarction 13. This 
supports the statement that length of stay after an acute myocardial infarction is, as 
for many medical conditions, more a consequence of historical precedent than 
medical evidence. The consequence of this is care without any incremental 
medical benefit but considerable expense. According to the guidelines of the 
ACC/AHA, STEMI patients originally admitted to the coronary car unit who 
demonstrate 12 to 24 hours of clinical stability (absence of recurrent ischemia, 
heart failure or hemodynamically compromising dysrhythmias), should be 
transferred to the step-down unit were mostly there is no possibility for rhythm 
monitoring. Since compromising dysrhythmias are most concerning for the 
physician, these step down units are not necessarily safe places to stay.  
A difficulty for showing that an early discharge strategy has safety equal to a 
routine hospital discharge strategy is the very large sample size required. This is 
presumably why there are only a few relatively small randomized trials concerning 
early discharge strategy. In the PAMI 2 trial 14, 471 low risk patients (<50% of 
screened patients; age < 70 years, no persistent arrhythmia, no triple vessel 
disease, ejection fraction > 45%, and successful reperfusion) were randomly 
assigned to early discharge or conventional care. Early discharge was applied to 
60% of the randomly assigned patients because of physician preference or patient 
refusal. Safety of early discharge was demonstrated by the very low 6-month 
mortality rate. Further review of the literature 15,16 shows that there is no evidence 
for improved outcomes with lengths of stay of more than 72 hours in low risk 
patients after myocardial infarction. In addition, patients with non ST-elevation 
myocardial infarction (NSTEMI) without complications can even be discharged on 
the day after coronary intervention 17. Since the mechanism underlying both STEMI 
an NSTEMI is presumably the same, it is likely that for selected low-risk STEMI 
patients, an equal discharge protocol as for NSTEMI patients is safe.  
As described earlier, another problem with early discharge is to determine which 
STEMI patient is sufficiently low risk to go home. As stated before, there have been 
 
 
       






introduced several bedside scores for risk stratification of patients with STEMI 
However, these risk scores have been developed in patients treated with medical 
therapy, with or without thrombolysis, without taking into account the procedural 
variables that significantly affect the outcome of these patients. In our study, we 
used the Zwolle risk score. This score is only based on coronary anatomy and flow 
parameters and can be applied immediately after the PTCA procedure and 
therefore is suitable for early identification of a patient that is a possible candidate 
for early discharge. 
As a consequence of earlier discharge, the demand for an intensive cardiac 
rehabilitation programs increases. In our study, patient counselling by the cardiac 
rehabilitation department started the day after discharge and continues at intensive 
follow up visits. Patient counselling focussed on information supply, compliance 
with taking medication, and smoking cessation. The cardiac rehabilitation program 
provided counselling on risk factor modification in the secondary prevention of 
ischemic heart disease, such as smoking, blood pressure, lipid management, 
physical activity, weight and DM management. In addition patients were included in 
an exercise program that consist of weekly ECG-monitored exercise sessions for 8 
to 12 weeks. The goals of these sessions were to develop and teach an 
individualized exercise prescription that is both safe and effective, to initiate 
interventions aimed at reducing coronary risk factors, and to identify and manage 
the psychosocial problems that commonly affect the cardiac patient. If necessary, 
additional individual psychosocial intervention was performed. 
The demand for these services should continue to increase as hospital stays 
become shortened, the population ages, and more advanced cardiac interventions 
become routinely available. 
In addition, it is known that even a short course of cardiac rehabilitation program is 
cost effective in improving long-term quality of life in patients with recent 
myocardial infarction or percutaneous coronary intervention 18. 
As coronary disease in its various forms of presentation is associated with a 
reduction in the patients' own perception of their QOL, QOL is an important 
measure of effectiveness of treatment. In our study we used the QLMI . The QLMI 
 
 
       





was developed and tested to evaluate a comprehensive cardiac rehabilitation 
programme for patients after myocardial infarction. It comprises 24 items that were 
selected after being rated as important by patients and clinicians. Two questions 
from QLMI (illustrating its disease specific nature) are: "In the past two weeks, how 
much time did you feel very confident that could deal with your heart problem?" and 
"During the last two weeks how much have you been limited in doing sports or 
exercise as a result of your heart problem?". These represent three subscales with 
scores ranging from 0-7, where higher scores represent higher functioning. In our 
study we found excellent QOL scores as compared tot 404 Dutch patients in who 
the same questionnaire was taken after myocardial infarction, CABG or PTCA. This 
might be explained by the young age and limited infarction size with good left 
ventricular rest function in our population. This contributes to a good prognosis, 




We conclude that by using the proposed prognostic index, patients may be 
stratified into an appropriate low risk group soon after admission to a coronary care 
unit. In these patients hospital discharge on the day after admission in combination 
with outpatient visits and a revalidation programme is feasible and offers a safe 
and patient-friendly alternative to the usual 3 to 4 days of in hospital care. This 
strategy at least doesn’t have any apparent negative effect on quality of life or 
secondary prevention goals and presumably has a positive effect. For future 
purposes we will continue “early discharge” in selected patients at our hospital and 
we will investigate possible inclusions of other hospitals. 
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In chapter 2, the beneficial effects of nitrates were discussed. We concluded that, 
based on previous studies with nitrates, nitrates can effectively control symptoms 
of angina pectoris and can be safely used for long term treatment. IR-SR 
isosorbide mononitrate has a rapid onset of action, is clinically efficient, and might 
provide better quality of life than the conventional ISMN/ISDN. However, tolerance 
with continued use of the formulation has not yet been reported and long-term 
efficacy data both of isosorbide mononitrate IR-SR and conventional ISMN/ISDN 
are limited so far. Therefore, we performed relatively large studies in patients with 
angina pectoris, the DUtch Mononitrate Quality of Life (DUMQOL) and International 
Quality Of Life assessment of patients with Angina pectoris on Nitrate therapy 
(IQOLAN) study. These studies are discussed in chapter 3 to 6. 
 
The purpose of chapter 3 was to compare the effects of a multiple and once daily 
formulation of nitrate therapy on the quality of life and to identify the influence of 
certain patient characteristics on the quality of life. In this retrospective study from 
the Dutch Mononitrate Quality of Life (DUMQOL) Study Group, the effects of 
multiple-dose (2 to 3 times daily 10 to 20 mg ) and once-daily nitrate therapy 
(sustained-release isosorbide mononitrate 50 mg) on the quality of life were 
evaluated in 1350 patients with stable angina pectoris. Patients were requested to 
complete a self-administered quality of life questionnaire after three months and 
after 6 months of treatment. The physician reported the actual patient 
characteristics. A multiple regression analysis was performed to assess which 
patient characteristics significantly influenced the overall quality of life. The results 
of this analysis showed that age did not influence the better benefit. Neither did 
gender, rhythmic disturbances, peripheral artery disease, or the concomitant use of 
calcium channel blockers or beta-blockers. New York Heart Association angina 
classification was an independent variable: patients with a class I or II benefited 
less than did patients with class III or IV (P=0.02). Obese patients as well as 
hypertensive patients benefited less (P=0.04 and 0.02), and smokers tended to 
benefit less (P=0.08). In contrast, cholesterolemia and diabetes mellitus improved 
the beneficial effect of nitrates on quality of life (P= 0.03 and 0.05). We concluded 
 
 
       





that patients with severe angina pectoris benefit better from nitrate therapy than do 
patients with New York Heart Association class I-II. Also, patients with coronary 
artery disease and concomitant diabetes mellitus or cholesterolemia may better 
benefit from nitric oxide-donor therapy than patients without such concomitant 
conditions do. In contrast, we concluded that patients with concomitant obesitas, 
hypertension, or smokers may benefit less. 
 
In chapter 4 we assessed whether the DUMQOL data could be generalized across 
nations and times. In addition, we assessed the effects on patients' satisfaction 
with disease state and on heart failure class. Therefore, patients from hospitals in 
Germany, Portugal, and the Czech Republic were treated for 3 months with 2-4 
times daily 10-20 mg isosorbide mononitrate/dinitrate and, subsequently, with once 
daily 50-120 mg isosorbide mononitrate/dinitrate for three more months. A QOL 
questionnaire, based on Wiklund's exercise tolerance index, Stewart's Short Form 
Questionnaire, and Dupuy's psychological well-being index, was completed after 3 
and 6 month treatment. In addition, patients' self-rated satisfaction with the current 
disease state, their treatment preference, and their New York Heart Association 
(NYHA) anginal and heart failure class were assessed twice. Of the 1045 patients 
included, 1010 (97%) completed the study. After three months of once-daily nitrate 
therapy the QOL-scores showed a significantly better improvement in all of the 
domains addressed, than did multiple daily dose treatment (p<0.0001). In addition, 
anginal and heart failure classes improved significantly better (p<0.0001). So did 
patient compliance as estimated by the percentages of patients forgetting to take 
their medication (59.6 versus 42.2%, p<0.0001), patients' self-rated satisfaction 
(30.5 versus 10.1% , p<0.0001), and patients' preference for the once-daily nitrate 
regimen (77.4 versus 3.6 %, p<0.0001). We concluded that once-daily nitrate 
treatment provides better NYHA anginal class, patient compliance, and QOL than 
does multiple daily dose treatment. These better benefits can be observed across 
nations and times. In addition to QOL indexes, patients' self-rated satisfaction with 
disease state improved, and so did NYHA heart failure class.  
 
 
       





As stated in chapter 3, we found in a retrospective study from the Dutch 
Mononitrate Quality of Life (DUMQOL) Study Group that anginal patients with 
concomitant diabetes or hypercholesterolemia derived more benefit from changing 
over to a once daily nitrate treatment regimen, than did anginal patients without. In 
Chapter 5 we assessed this issue prospectively. In an open-label study, patients 
with stable angina pectoris (SAP) from facilities in Germany, Portugal, and the 
Czech Republic were treated for 3 months with multiple daily dosages and 
subsequently for 3 more months with once daily isosorbide mono-/dinitrate 
(ISMN/DN). After the first and second 3 month period they were assessed by a 
validated QOL-battery including the domains, mobility, side-effect, life-satisfaction, 
anginal-pain, and psychological-distress. In the 1045 patients who participated in 
the study mean summary domain-scores varied from 5-16 points, score 
improvements from 1.6 to 4.3 points. In the patients with concomitant hypertension 
and the smokers domain-scores improved less than they did in the patients 
without, with differences in domain-score improvements up to 1.0 points (p<0.001), 
which is substantial considering the range of improvement being between 1.6 and 
4.3 points. In the patients with diabetes mellitus or hypercholesterolemia a 
reversed pattern was observed with differences in domain-score improvements up 
to 0.4 points (p<0.05).  
We concluded that anginal patients with diabetes or hypercholesterolemia derived 
more benefit from an asymmetric regimen of isosorbide mono/dinitrate than did 
patients without. Anginal patients with hypertension or smokers did less so. The 
results are in line with the findings of chapter 3. We suggest that differences in 
endothelial function may be involved.  
 
From the previous chapters we concluded that asymmetric nitrate dosages 
provided better therapeutic efficacy in patients with stable angina pectoris, than did 
multiple daily dosages. Anginal patients with cardiovascular comorbidities may 
particularly benefit from nitric-oxide- (NO) donor therapy due to the underlying 
impairment of endothelium-dependent NO-activity. The objective of chapter 6 was 
to compare QOL and exercise capacity before and after replacement of multiple 
 
 
       





daily with once-daily nitrate therapy and to investigate the influence of 
cardiovascular co morbidities on the observed changes in a larger, international 
study group. Out-patients with stable angina pectoris and at least three months 
pre-treatment with 3 times daily 20-40 mg of isosorbide mono-or dinitrate were 
switched to the equivalent single daily dose of the compound early in the morning. 
We assessed predefined QOL-indices, painfree walking distances, New York Heart 
Association (NYHA) anginal class, and the influence of cardiovascular risk factors 
and comorbidities. Standard multi- and univariate methods were applied. Of 2675 
patients included, 2574 (96.2%) completed the study. After three months once-
daily nitrate mean QOL-scores improved from 10 to 19% (p<0.0001 for all of the 
QOL-domains). The percentage of patients in NYHA anginal class I increased by 
23.4% (p<0.0001), while exercise capacity increased from a median painfree 
walking distance of 300 to 500 m (p<0.001). In patients with concomitant 
hypertension or hypercholesterolemia anginal class improved better (27.4 and 24.6 
%, both p<0.001). Young age, advanced NYHA anginal class, 
hypercholesterolemia and coronary artery disease (CAD) in the family were 
important independent determinants of the improved QOL.  
We concluded that replacement of multiple-dose with once-daily nitrate treatment 
resulted in an improved QOL, anginal NYHA class, and exercise capacity. Patients 
with concomitant hypertension or hypercholesterolemia particularly benefited from 
the asymmetric dosage regimen. However, the results of the multivariate analysis 
are not in line with the findings in chapter 3 and 5. Further research is needed to 
asses this discrepancy. 
 
Chapter 7 focussed on QOL and social comparison in patients with stable chronic 
congestive heart failure. Independent determinants of QOL in these patients have 
been recognized and include factors like severity of medical condition, comorbidity, 
and concomitant medication. Psychosocial factors, like “ability to cope with the 
unpleasantness of the medical condition”, “want of information”, and “social 
identification” have important influence on self-perceived well-being, but their 
influence on health-related QOL domains and self-perceived QOL in patients with 
 
 
       






heart failure have not been systematically studied. In this chapter we assessed 
correlation between such psychosocial factors and QOL in patients with heart 
failure. Therefore, patients from the outpatient heart failure clinic of the Martini 
Hospital , a 1000-bed community hospital in the city of Groningen, Netherlands, 
were included if their ejection fractions were <40% and their medical diagnosis 
according to their cardiologists was stable chronic congestive heart failure. The 
following QOL-estimators were applied: Pearlin’s Mastery Scale, Stewart’s Short 
Form 36 Quality of Life Questionnaire, Dupuy’s Index of Well-being, Cantrill’s Self-
perceived Quality of Life Scale, Mester’s Want of Information Scale. Internal 
consistency of the multi-item scales were estimated by Cronbach’s alphas. Linear 
and multiple linear regression analyses were performed of the data. In total, sixty 
patients were enrolled, 41 males and 19 females, average age 68 years (range 51-
84 years). “Ability to cope with the unpleasantness of the medical condition” was 
not only an independent determinant of self-perceived and health-related 
QOL(both p<0.001), but also of each domain of health related QOL separately 
(p<0.001 for each domain). Lack of “adequate medical information” and “negative 
social identification” (the identification with counterparts who are doing worse) were 
negative predictors of “ability to cope” (p<0.01 and <0.001 resp). “Negative social 
identification” also was an independent determinant of self-perceived QOL, both 
unadjusted and after adjustment for “ability to cope” and “adequate medical 
information”.      
Relevant recommendations from this chapter to be considered by cardiologists 
during everyday office-hours could included: 1. Patients who express having 
difficulties to cope with the unpleasant aspects of their underlying heart condition, 
have low health-related QOL as well as low self-perceived QOL. 2. Adequate 
medical information given is a significant contributor to both better “ability to cope” 
and better self-perceived QOL. 3. Avoiding to identify oneself with counterparts 
who are doing worse, and, instead, starting to identify oneself with counterparts 
who are doing better, are significant contributors to both better “ability to cope” and 
better self-perceived QOL. 
 
 
       





From the previous chapter it was concluded that providing adequate medical 
information and avoiding patients to identify themselves with fellow-sufferers were 
significant contributors to better quality of life in patients with stable chronic 
congestive heart failure. In previous studies, gender and level of psychic tension 
were significant predictors of QOL in cardiac patients. We don’t know (1) whether 
we can improve QOL by increasing patients’ ability to cope with the unpleasant 
aspects of the underlying condition, (2) whether gender and level of psychic 
tension interact or act independently. In chapter 8 we assessed both questions. For 
that purpose, 38 patients on the waiting list for coronary angiography were 
assessed with validated test batteries. To increase the patients’ ability to cope, they 
were randomly assigned to read either (1) the comments of a patient previously 
successfully treated or (2) general information. The former information, unlike the 
latter, was assumed to improve coping ability and, thus, provide better QOL. 
Homogeneity of the patient group was estimated by Cronbach’s alphas. For 
analysis linear regression and general factorial analyses of variance were applied. 
We found that the group was psychologically homogeneous as indicated by 
Cronbach’s alphas being, generally, over 75%. There was a significant or close to 
significant association of presence of coping information with a better mobility, 
social performance and self-perceived QOL (p<0.05, p<0.06, and p = 0.10).High 
levels of psychic tension were associated with low self-perceived QOL and low 
psychological scores (both p<0.02). Female gender was associated with lower 
mobility, lower psychological scores and lower overall QOL (p<0.05, p<0.02 and 
p<0.05). A significant or close to significant interaction was observed between 
gender and psychic tension as combined determinants of self-perceived QOL, 
mobility index, and overall QOL index (p<0.03, p<0.09, and p<0.05). Separate 
assessments of these determinants showed that the female gender was the 
strongest determinant of low QOL. We concluded that in patients on the waiting list 
for coronary angiography, an increased ability to cope with the unpleasant aspects 
of a possible underlying heart condition improves QOL. In addition, female gender 
and a high level of psychic tension places patients at risk of low QOL.  
 
 
       






Chapter 9 refers to a feasibility study concerning early discharge and QOL 
evaluation after acute myocardial infarction. The objective of this study was to 
investigate the feasibility of a short-stay protocol after myocardial infarction (MI) 
and primary PTCA in a selected low-risk population and to evaluate QOL. Patients 
eligible for the study had acute MI, treated successfully with primary PTCA. 
Inclusion criteria included single vessel disease, TIMI 3 flow after the procedure 
combined with a good myocardial blush and absence of heart failure. Patients 
meeting the inclusion criteria were discharged 24 to 36 hours after admission, and 
visited the outpatient clinic (where they were seen by a specialised nurse) on the 
third and fourth day. Consecutively, they were enrolled in the standard revalidation 
programme. We evaluated re-infarction, re-admission or visits to the emergency 
department in the follow-up period of three months. Furthermore, we evaluated 
quality-of-life scores and secondary prevention goals at the end of the follow-up 
period. In total, 46 patients were included in the study. Mean age was 55 yrs (37-73 
yrs), 26 patients (57%) were current smokers, 4 patients (9%) had diabetes 
mellitus and 13 patients (28%) were known with hypertension. There were 12 
patients with anterior infarction (26%). Mean CK was 1016 U/L (range 95-4333), 
CK-MB 118 U/L (range 13-374). Mean left ventricular ejection fraction 1 week after 
infarction was 59% (range 39%-77%). Patients were discharged after a mean of 29 
hours (standard deviation 6.6, range 20-48 hours). During the follow-up period, 
there were no re-infarctions or re-admissions. After three months 17 of the 26 
patients who smoked on admission had not resumed smoking. Mean total 
cholesterol was 3.9 (on admission 5.4) and mean blood pressure 127/75 (on 
admission 138/83). On exercise testing, none of the patients showed signs of 
myocardial ischemia and mean performance was 97% of the expected value. 
Quality-of-life scores on 3 scales (emotional, physical and social wellbeing), taken 
both 1 week after discharge and after 3 months, were excellent. We concluded that 
after acute MI and primary PTCA, hospital discharge on the day after admission in 
combination with outpatient visits and a revalidation programme is feasible and 
offers a safe and patient-friendly alternative to the usual 3 to 4 days of in hospital 
 
 
       










       



































Belangrijke doelstellingen bij de behandeling van coronaire hartziekten zijn niet 
alleen de primaire en secundaire preventie van een myocardinfarct, maar ook 
afname van pijn en de toename van inspanningstolerantie van de patiënt: om die 
toename te bereiken kunnen bij deze patiëntengroep organische nitraten worden 
gebruikt. Een prototype daarvan is nitroglycerine. Hoewel vele andere vormen van 
anti-ischemische therapie, zoals beta-blokkerende middelen en calcium-
antagonisten, hun waarde bewezen hebben, vormen nitraten de hoeksteen van 
anti-angineuze therapie. De effectiviteit van deze middelen staat al meer dan 100 
jaar vast. Alfred Nobel (1833-1896), een Zweedse chemicus, was de eigenaar van 
het patent op de productie van nitroglycerine, een stof die aanvankelijk als 
explosief werd gebruikt. Hij beschreef de stof als volgt: “Het is een reukloze, 
bruinige vloeibare substantie die geproduceerd wordt door de nitrilatie van 
glycerine. Het is stabiel bij kamertemperatuur, maar het kan exploderen in het 
geval van push or hit.” De eerste experimenten met nitroglycerine waren nogal 
traumatiserend. In 1884 explodeerde een van de fabrieken van Alfred Nobel. 
Daarbij kwam zijn broer om het leven. In die dagen werden ook de eerste 
symptomen van nitraattolerantie gerapporteerd bij arbeiders in de nitroglycerine 
fabrieken. Zij hadden typische hoofdpijnklachten, vooral op maandag, wanneer ze 
na een vrij weekend weer aan het werk gingen. Alfred Nobel doneerde zijn gehele 
vermogen aan de “Nobel Foundation”, die sinds 1901 elk jaar de Nobelprijzen ter 
beschikking stelt aan de wetenschap. De eerste die de gunstige effecten van 
nitroglycerine bij de mens beschreef, was Lauder Brunton in 1867. Hij gebruikte 
destijds een nitraatzetmeel-verbinding om angineuze klachten te behandelen. In de 
laatste decennia is de kennis over de functie en de werking van nitroglycerine 
drastisch toegenomen. Stikstofoxide (NO) blijkt het actieve molecuul te zijn dat 
verantwoordelijk is voor vasodilatatie. Dit oxide wordt ook door het endotheel zelf 
geproduceerd (endothelian derived relaxation factor (EDRF) = nitric oxide (NO). 
 
In hoofdstuk 2 van dit proefschrift werden de effecten van nitraten besproken. 
Hierbij werd geconcludeerd dat, gebaseerd op eerdere studies, nitraten effectief 
zijn in het verlichten van symptomen van angina pectoris en dat ze veilig gebruikt 
 
 







kunnen worden voor een chronische behandeling. Isosorbidemononitraat eenmaal 
daags met een 30% snelle afgifte gecombineerd met een 70% langzame afgifte 
blijkt klinisch efficiënt te zijn en kan wellicht leiden tot een betere kwaliteit van leven 
bij mensen met angina pectoris dan de meermaaldaagse toedieningsvorm van 
nitraten. Daarnaast is er nog weinig bekend over de lange termijn effecten van 
zowel de nitraten met eenmaaldaagse gereguleerde afgifte als de conventionele 
nitraten met meermaal daagse toediening. Derhalve zijn er twee relatief grote 
studies opgezet bij patiënten met stabiele angina pectoris, de Dutch Mononitrate 
Quality of Life (DUMQOL) en de International Quality Of Life assessment in 
patients with Angina pectoris on Nitrate therapy (IQOLAN) studie. De resultaten 
van deze studies werden besproken in de hoofdstukken 3 tot en met 6. 
 
Het doel van hoofdstuk 3 was het vergelijken van de effecten van meermaal 
daagse toediening en eenmaal daagse dosering op de kwaliteit van leven en het 
identificeren van bepaalde patiëntkarakteristieken die hier van invloed op zijn. 
Hiertoe werden de effecten van meermaaldaagse toediening (2 tot 3 maal daags 
10-20 mg) en eenmaaldaagse toediening (sustained release isosorbidemononitraat 
50 mg) op de kwaliteit van leven bij 1350 patiënten met stabiele angina pectoris 
bekeken. Patiënten werden gedurende drie maanden behandeld met de 
meermaaldaagse vorm van nitraat. Vervolgens werden patiënten drie maanden 
behandeld met een eenmaaldaagse vorm. Patiënten werd gevraagd een kwaliteit 
van leven vragenlijst na drie en na zes maanden in te vullen. De vragenlijst was 
gebaseerd op de “Wiklund`s exercise tolerance index”, “Stewart`s Short Form 
Questionnaire” en “Dupuy`s psychological well-being index”. Daarnaast werden de 
voorkeur van behandeling van de patiënt, de NYHA angina pectoris klasse en de 
NYHA hartfalen klasse geëvalueerd. De actuele patiëntkarakteristieken werden 
door de behandelend cardioloog verzameld. Er werd een multipele regressie-
analyse toegepast om te evalueren welke patiëntkarakteristieken een significante 
invloed hadden op de kwaliteit van leven. Leeftijd, geslacht, voorkomen van 
ritmestoornissen, perifeer vaatlijden en co-medicatie (bètablokkerende middelen of 
calciumantagonisten) hadden geen significante invloed, maar een aantal andere 
 
 
       






factoren had dat wel. Zo bleek de NYHA klasse een onafhankelijke variabele te 
zijn: patiënten met NYHA klasse III of IV bleken extra baat te hebben bij een 
eenmaaldaagse dosering en dus een grotere verbetering van de kwaliteit van 
leven te krijgen met monotherapie dan patiënten met NYHA klasse I of II (p=0.02). 
Zowel obesitas (p=0.02), hypertensie (p=0.04) als roken (p=0.08) gaven een 
significante verslechtering van de kwaliteit van leven. Dit in tegenstelling tot 
mensen met hypercholesterolaemie en diabetes mellitus (p=0.04 en 0.02), deze 
patiënten bleken juist weer meer baat te hebben bij een eenmaaldaagse 
nitraattherapie. We concludeerden dan ook dat patiënten met ernstige angina 
pectoris meer baat hebben bij eenmaaldaagse nitraattherapie dan patiënten met 
angina pectoris NYHA klasse I of II. Dit geld tevens voor patiënten met coronaire 
hartziekten en bijkomende diabetes mellitus of hypercholesterolaemie. Dit in 
tegenstelling tot patiënten met obesitas, hypertensie en roken als risicofactor: deze 
patiënten profiteerden minder van de wisseling van meermaaldaagse naar 
eenmaaldaagse nitraattherapie. 
 
In hoofdstuk 4 evalueerden we of de data van het DUMQOL onderzoek 
reproduceerbaar waren in andere Europese landen. Hiertoe werden patiënten met 
stabiele angineuze klachten uit ziekenhuizen in Duitsland, Portugal en de 
Tsjechische republiek gedurende drie maanden behandeld met een 
meermaaldaagse nitraattherapie. Vervolgens werd gedurende drie maanden 
overgegaan op de behandeling van de angineuze klachten met een eenmaal 
daagse dosering van nitraat met gereguleerde afgifte. Een kwaliteit van leven 
vragenlijst werd afgenomen na drie en zes maanden. Van de 1045 geïncludeerde 
patiënten waren er 1010 (97%) die de follow-up voltooiden. Na drie maanden 
behandeling met een eenmaaldaagse nitraattherapie was er een significante 
verbetering van kwaliteit van leven zichtbaar (p<0.0001). Tevens was er een 
significante verbetering van zowel de NYHA angina pectoris als de NYHA hartfalen 
klasse (p<0.0001). De compliantie met betrekking tot het nemen van de medicatie 
nam toe, daar de patiënten aangaven minder vaak hun medicatie te vergeten 
(59.6% versus 42.2%). Daarnaast bleek het algeheel welbevinden significant beter 
 
 







te zijn bij eenmaaldaagse nitraattherapie. Patiënten gaven hier dan ook de 
voorkeur aan (77.4% voorkeur aan eenmaaldaagse dosering, 3.6% voorkeur aan 
meermaal daagse dosering). We concludeerden dat eenmaaldaagse 
nitraattherapie leidt tot een verbetering van de NYHA angina pectoris klasse, een 
verbetering van de patiënt-compliantie en een verbetering van de kwaliteit van 
leven. Deze bevindingen zijn vergelijkbaar tussen verschillende Europese 
bevolkingsgroepen. Daarnaast verbeterden het algemeen welbevinden en de 
NYHA hartfalen klasse bij het overgaan van meermaaldaagse op eenmaaldaagse 
toediening van nitraten. 
 
Zoals vermeld in hoofdstuk 3, liet de analyse van de DUMQOL data zien dat 
patiënten met stabiele angineuze klachten en diabetes mellitus of 
hypercholesterolaemie meer baat hadden bij de omzetting van meermaaldaagse 
nitraattherapie naar eenmaaldaagse nitraattherapie dan patiënten zonder diabetes 
mellitus of hypercholesterolaemie. In hoofdstuk 5 werd dit prospectief onderzocht. 
In een open-label onderzoek werden patiënten met stabiele angina pectoris uit 
Duitsland, Portugal en Tsjechië gedurende drie maanden behandeld met 
meermaaldaagse doseringen nitraat. Vervolgens werd overgegaan op een 
eenmaaldaagse behandeling met gereguleerde afgifte. Na de eerste en tweede 
periode van drie maanden werd kwaliteit van leven gemeten. De kwaliteit van leven 
werd gemeten aan de hand van verschillende domeinen. Deze domeinen waren: 
mobiliteit, bijwerkingen, algeheel welbevinden, angina pectoris en psychische druk. 
De gemiddelde scores op ieder domein varieerden van 4 tot 16 punten. De scores 
namen toe van 1.6 tot 4.3 punten. Bij patiënten met hypertensie en bij rokers 
verbeterde de score significant minder dan bij patiënten zonder hypertensie of niet-
rokers. Het verschil bedroeg maximaal 1.0 punt (p<0.001), hetgeen aanzienlijk is 
daar de range van verbetering zich tussen de 1.6 en 4.3 punten bevond. Dit 
verschil was vooral te zien bij patiënten uit Duitsland. Bij patiënten met diabetes 
mellitus of hypercholesterolaemie werd een tegenovergesteld patroon gezien. De 
verbetering van kwaliteit van leven met betrekking tot de verschillende domeinen 
bedroeg tot 0.4 (p<0.05) ten opzichte van patiënten zonder diabetes mellitus of 
 
 
       






hypercholesterolaemie. We concludeerden dat patiënten met diabetes mellitus of 
hypercholesterolaemie meer baat hadden bij het overgaan van meermaaldaagse 
op eenmaaldaagse nitraattherapie. Voor patiënten met hypertensie en rokers gold 
het omgekeerde. De bevindingen kwamen overeen met de bevindingen in 
hoofdstuk 3. Wellicht dat verschillen in endotheelfunctie hierbij betrokken zijn.  
 
Uit de voorgaande hoofdstukken concludeerden we dat eenmaaldaagse 
nitraattherapie een beter therapeutisch effect had bij patiënten met stabiele 
angineuze klachten dan meermaaldaagse nitraattherapie. Patiënten met 
angineuze klachten en co-morbiditeit hadden wellicht extra baat bij een 
eenmaaldaagse nitraattherapie door onderliggende disfunctie van het endotheel. 
Het doel van hoofdstuk 6 was om de kwaliteit van leven en inspanningstolerantie 
voor en na de vervanging van de meermaaldaagse door de eenmaaldaagse vorm 
van nitraat te vergelijken en hierbij tevens te kijken naar de invloeden van de 
cardiovasculaire co-morbiditeit op de waargenomen veranderingen in kwaliteit van 
leven. Dit alles in een grotere en internationale patiënten populatie. De landen die 
meededen aan het onderzoek zijn: Duitsland, Portugal, Tsjechië, Letland, Rusland 
en China. Poliklinische patiënten met stabiele angina pectoris die tenminste drie 
maanden behandeld waren met een meermaaldaagse dosering nitraat, werden 
omgezet naar een eenmaaldaagse dosering nitraat in de ochtend. Van te voren 
gedefinieerde kwaliteit van leven indices als pijnvrije loopafstand, angina pectoris 
NYHA klasse en de invloed van cardiovasculaire risicofactoren en co-morbiditeit 
werden geëvalueerd. Standaard uni-variate en multi-variate analyses werden 
toegepast. Van de 2675 patiënten die werden geïncludeerd waren er 2574 (96.2%) 
die de complete follow-up doorliepen. Na drie maanden behandeling met 
eenmaaldaagse nitraattherapie verbeterden de kwaliteit van leven scores 10-19% 
(p<0.001 voor alle kwaliteit van leven domeinen). Het percentage patiënten met 
NYHA angina pectoris klasse I nam toe met 23.4% (p<0.001), de pijnvrije 
inspanningstolerantie nam toe van 300 naar 500 meter (p<0.001). Bij patiënten met 
hypertensie en hypercholesterolaemie was er sprake van een significant grotere 
verbetering (resp. 27.4 en 24.6% meer patiënten in NYHA klasse I, p<0.001). 
 
 







Zowel een jongere leeftijd, hogere NYHA klasse, hypercholesterolaemie en een 
positieve familie-anamnese voor hart- en vaatziekten waren onafhankelijke 
determinanten van een betere kwaliteit van leven. We concludeerden dat het 
vervangen van meermaaldaagse behandeling met nitraten door een eenmaal 
daagse behandeling resulteerde in een verbetering van de kwaliteit van leven, de 
NYHA klasse en de inspanningstolerantie. Uit dit onderzoek bleek dat patiënten 
met hypercholesterolaemie of hypertensie extra baat hebben bij een eenmaal 
daagse behandeling. Dit is echter niet geheel in overeenstemming met de 
bevindingen in de hoofdstukken 3 en 5. De multivariate analyse van de DUMQOL 
50, zoals beschreven in hoofdstuk 3, is tamelijk grof omdat scores van 
verschillende domeinen zijn opgeteld. Bij patiënten met adipositas bijvoorbeeld zal 
het mobiliteitsdomein grotere problemen geven dan bij slanke mensen. Echter de 
bevindingen van de IQOLAN met data uit Duitsland, Portugal en Tsjechië laten 
dezelfde resultaten zien als bij de DUMQOL multivariate analyse. Een verklaring 
voor het niet bevestigen van deze data in het uiteindelijke IQOLAN onderzoek, 
zoals beschreven in dit hoofdstuk, is mogelijk het genetische verschil tussen de 
bevolkingsgroepen in de verschillende landen. Daarnaast bestaat er ook een groot 
verschil in medisch handelen tussen de cardiologen in de verschillende landen. 
Verder spelen cultuurgebonden factoren mogelijk een rol. Niettemin leverden de 
huidige analyses van de resultaten interessante conclusies op. Patiënten met een 
hogere NYHA klasse of hypercholesterolaemie lijken extra gebaat te zijn bij een 
eenmaal daagse nitraattherapie. Dat overige patiëntengroepen dit extra voordeel 
mogelijk missen, is op zichzelf geen reden om aan hen de optimale nitraattherapie 
te ontzeggen. 
 
In hoofdstuk 7 werd gekeken naar de kwaliteit van leven en sociale vergelijking bij 
patiënten met stabiel chronisch hartfalen. Er werd onderzocht hoe deze patiënten 
hun kwaliteit van leven beoordeelden en door welke psychologische factoren de 
kwaliteit van leven beïnvloed werd. De psychologische factoren die geëvalueerd 
werden zijn “het ervaren van controle over de medische conditie”, “behoefte aan 
objectieve medische informatie” en “sociale vergelijking”. Hiertoe werden 
 
 
       






opeenvolgende patiënten met stabiel chronisch hartfalen op de polikliniek van het 
Martini Ziekenhuis te Groningen geïncludeerd. De volgende kwaliteit van leven 
instrumenten werden gebruikt: Pearlin`s Mastery Scale, Stewart`s Short Form 36 
Quality of Life questionnaire, Dupuy`s Index of Well-being, Cantrill`s Self perceived 
QOL Scale en de Mester`s want of information scale. Interne consistentie van de 
multi-item domeinen werd bepaald middels Cronbach`s alphas. Lineaire en 
multipele lineaire regressie analyses werden verricht. In totaal werden 60 patiënten 
geïncludeerd. De “ervaren controle op de medische conditie“ was een sterke 
onafhankelijke voorspeller voor de kwaliteit van leven. Gebrek aan “objectieve 
medische informatie” en “negatieve sociale vergelijking” (de identificatie met 
lotgenoten die er slechter aan toe zijn) waren negatieve voorspellers voor “de 
ervaren controle”. “Negatieve sociale vergelijking” was ook een onafhankelijke 
voorspeller voor kwaliteit van leven. Belangrijke conclusies uit dit onderzoek waren: 
1. Patiënten die aangeven weinig controle te hebben op de ongunstige effecten 
van hartfalen hebben een mindere kwaliteit van leven 2. Het geven van goede 
medische informatie draagt bij aan een betere controle op de ongunstige effecten 
van hartfalen en zodoende tot een betere kwaliteit van leven 3. Het vermijden van 
vergelijken met lotgenoten die er slechter aan toe zijn en in plaats daarvan 
vergelijken met lotgenoten die er beter aan toe zijn draagt bij patiënten met 
hartfalen bij aan een significant betere kwaliteit van leven. 
 
Uit het vorige hoofdstuk werd onder meer geconcludeerd dat het geven van goede 
medische informatie en sociale vergelijking significant bijdragen aan de kwaliteit 
van leven bij patiënten met stabiel chronisch hartfalen. Eerder onderzoek heeft 
laten zien dat geslacht en psychische spanningen significante voorspellers zijn van 
kwaliteit van leven bij cardiale patiënten. In hoofdstuk 8 onderzochten we 1) of 
door het verbeteren van de coping de kwaliteit van leven verbeterd kan worden en 
2) of geslacht en psychische spanning een interactie vertonen dan wel of zij 
onafhankelijke variabelen voor kwaliteit van leven zijn. Hiervoor werden 38 
achtereenvolgende patiënten die werden aangemeld voor electieve diagnostische 
coronairangiografie geïncludeerd. Om de coping van de patiënten te verbeteren 
 
 







werden ze gerandomiseerd naar het lezen van 1) het commentaar van een patiënt 
die eerder een ongecompliceerde coronairangiografie had ondergaan, dan wel 2) 
algemene informatie. De veronderstelling was dat patiënten in de eerste groep een 
betere coping hadden en derhalve een betere kwaliteit van leven. Er bleek sprake 
van een borderline significante relatie tussen de “coping informatie” en een betere 
score op een drietal domeinen van kwaliteit van leven. Verhoogde psychische 
spanning ging gepaard met een mindere kwaliteit van leven. Een borderline 
significante interactie werd gezien tussen geslacht en psychische spanning. 
Univariate analyse liet zien dat het vrouwlijk geslacht de sterkste determinant was 
van een mindere kwaliteit van leven. We concludeerden dat bij patiënten op de 
wachtlijst voor coronairangiografie een toename van coping leidde tot een betere 
kwaliteit van leven. Daarnaast zijn vrouwelijk geslacht en hoge psychische 
spanningen een risicofactor voor een mindere kwaliteit van leven. Opgemerkt dient 
te worden dat de hoofdstukken 7 en 8 analyses betreffen in relatief kleine 
populaties, zodat de resultaten voorzichtig geïnterpreteerd moeten worden. 
Reproduceerbaarheid dient in een groter onderzoek getoetst te worden. 
 
In hoofdstuk 9 wordt een onderzoek beschreven waarbij patiënten met een 
doorgemaakt acuut myocardinfarct, die een ongecompliceerde primaire percutane 
coronaire interventie (PCI) ondergingen, reeds 24 tot 36 uur na opname werden 
ontslagen en daarna direct opgenomen in een hartrevalidatietraject. Het doel van 
het onderzoek was om het opgestelde protocol te evalueren. Hierbij werd tevens 
de kwaliteit van leven gemeten. Patiënten die in aanmerking kwamen voor het 
onderzoek waren door middel van een ongecompliceerde primaire PCI met goed 
resultaat behandeld voor een acuut myocardinfarct. Zij werden 24 tot 36 uur na 
opname ontslagen en direct opgenomen in een hartrevalidatieprotocol. Er werd 
gekeken naar recidief infarcten, heropnames en opnames op de Eerste Harthulp. 
Tevens werden kwaliteit van leven en secundaire preventiedoelen geëvalueerd. In 
totaal werden 46 patiënten geïncludeerd. De gemiddelde leeftijd bedroeg 55 jaar 
(37-73). Er waren twaalf patiënten met een voorwand-myocardinfarct (26%). De 
gemiddelde CK-piek bedroeg 1016 U/L (range 95-4333) en de gemiddelde CKMB-
 
 
       






piek 118U/L (range 13-374). De gemiddelde linkerventrikel-ejectiefractie 1 week na 
het infarct was 59%. Na 3 maanden waren 17 van de 26 rokers nog steeds gestopt 
met roken. Ook de streefwaarden voor bloeddruk en cholesterol werden bereikt. 
Fietsergometrie liet in de gehele groep een goede inspanningstolerantie zonder 
aanwijzingen voor recidief ischemie zien. De kwaliteit van leven scores, verdeeld 
over 3 domeinen (emotioneel, psychisch en sociaal welbevinden) en geevalueerd 
1 week en 3 maanden na ontslag, waren uitstekend. We concludeerden dan ook 
dat, in een selecte patiëntengroep, na een myocardinfarct waarvoor behandeling is 
geweest middels primaire PCI, ontslag 24 tot 36 uur na opname een 
patiëntvriendelijk alternatief is voor de normale 3 tot 4 dagen opname, zonder 
ongunstige effecten op de kwaliteit van leven of secundaire preventiedoelen 
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